Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 18, 2026.

Inflammation in Renal Diseases: New and Old Players

Vinicius Andrade-Oliveira, Orestes Foresto-Neto, Ingrid Kazue Mizuno Watanabe and 2 more

Frontiers in Pharmacology · 2019 · Review · CC BY

doi:10.3389/fphar.2019.01192

Abstract

Inflammation, a process intimately linked to renal disease, can be defined as a complex network of interactions between renal parenchymal cells and resident immune cells, such as macrophages and dendritic cells, coupled with recruitment of circulating monocytes, lymphocytes, and neutrophils. Once stimulated, these cells activate specialized structures such as Toll-like receptor and Nod-like receptor (NLR). By detecting danger-associated molecules, these receptors can set in motion major innate immunity pathways such as nuclear factor ĸB (NF-ĸB) and NLRP3 inflammasome, causing metabolic reprogramming and phenotype changes of immune and parenchymal cells and triggering the secretion of a number of inflammatory mediators that can cause irreversible tissue damage and functional loss. Growing evidence suggests that this response can be deeply impacted by the crosstalk between the kidneys and other organs, such as the gut. Changes in the composition and/or metabolite production of the gut microbiota can influence inflammation, oxidative stress, and fibrosis, thus offering opportunities to positively manipulate the composition and/or functionality of gut microbiota and, consequentially, ameliorate deleterious consequences of renal diseases. In this review, we summarize the most recent evidence that renal inflammation can be ameliorated by interfering with the gut microbiota through the administration of probiotics, prebiotics, and postbiotics. In addition to these innovative approaches, we address the recent discovery of new targets for drugs long in use in clinical practice. Angiotensin II receptor antagonists, NF-ĸB inhibitors, thiazide diuretics, and antimetabolic drugs can reduce renal macrophage infiltration and slow down the progression of renal disease by mechanisms independent of those usually attributed to these compounds. Allopurinol, an inhibitor of uric acid production, has been shown to decrease renal inflammation by limiting activation of the NLRP3 inflammasome. So far, these protective effects have been shown in experimental studies only. Clinical studies will establish whether these novel strategies can be incorporated into the arsenal of treatments intended to prevent the progression of human disease.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 18, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Acute kidney injury (AKI) and chronic kidney disease (CKD) are highly prevalent conditions associated with significant levels of morbidity and mortality. According to the US Renal Data System, about 30 millions of Americans were afflicted with CKD in 2017, a prevalence of almost 15%. As to AKI, recent evidence indicates that it affects almost 60% of intensive care unit (ICU) patients, whereas its severity is directly related to mortality.

Although the mechanisms underlying CKD and AKI are quite distinct, clinical evidence suggests that the two conditions are inextricably interconnected. Inflammation, a process aimed in principle at detecting and fighting harmful pathogens, is a major pathogenic mechanism for both CKD and AKI. Both resident and circulating immune cells can interact with parenchymal renal cells to trigger an inflammatory response when subjected to stress, causing irreversible tissue damage and eventuating in organ failure. Thus, targeting inflammation constitutes a rational strategy in the management of both CKD and AKI.

Kidney Resident Immune Cells

The kidney harbors a variety of resident immune cells, which play an important role in the maintenance of tissue homeostasis. Dendritic cells (DCs), macrophages, regulatory T cells (Tregs), CD8, and NK lymphocytes, among other cell types, are in close contact with parenchymal cells ( Figure 1, left side). Once activated by external (for instance, microbial antigens) or by internal events, these cells produce inflammatory mediators that can initiate kidney disease and, concomitantly, trigger a regulatory response aimed at curbing inflammation, repairing tissue damage, and restoring homeostasis. For instance, microbial products and alarmins can bind to innate immune receptors on the surface of DC, leading these cells to secrete a number of chemokines and cytokines and to migrate to draining lymph nodes, where they can amplify the immune response by activating T lymphocytes (TH1 CD4+ and cytotoxic cells). At the same time, DCs can limit inflammation by stimulating the production of interleukin 10 (IL-10) by Treg lymphocytes. Another clear example of this dichotomous activity is given by macrophages, which, by sensing alarmins through innate immune receptors, can initiate/enhance inflammation via the M1 subset and, simultaneously, exert an anti-inflammatory effect via the M2 subset ( Figure 1, right side).

Role of Toll-Like Receptor– and Nod-Like Receptor–Dependent Pathways

Ischemia–reperfusion injury (IRI) is a major cause of AKI in ICU patients. Transcriptome analysis in whole tissue as well as cell-specific analysis using Cre/Lox techniques revealed that IRI is associated with a myriad of events ranging from organelle stress to activation of complex intracellular pathways. One of the earliest events in the development of IRI is sterile (nonmicrobial) activation of innate immune receptors such as TLRs (Toll-like receptors) and NLRs (Nod-like receptors). These structures, expressed in renal parenchymal cells as well as in resident immune cells, can recognize pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). Activation of these receptors triggers a number of intracellular pathways such as c-Jun N-terminal kinases (JNK), mitogen-activated protein kinase (MAPK), and nuclear factor kB (NF-ĸB), culminating with the secretion of proinflammatory cytokines and chemokines. Much of the current knowledge about the role of these receptors in AKI came from studies of knockout (KO) mice. Lack of TLR4 and/or TLR2, as well as of their adaptor molecule, myeloid differentiation factor 88 (MyD88), prevented the development of kidney injury in mice undergoing IRI. Available evidence indicates that activation of these receptors and the development of downstream inflammatory events follow the binding of alarmins released after cell injury and/or death. Accordingly, upregulation and blockage of one of these alarmins, high-mobility group box 1, was associated with aggravation and lessening of renal injury, respectively. A similar mechanism seems to be operative in murine models of sterile (cisplatin toxicity) and nonsterile (sepsis) AKI. Castoldi et al. showed that lack of TLR4, TLR2, and MyD88 limited renal damage in a sepsis model, mainly by decreasing the recruitment of neutrophils. In mice with cisplatin-induced AKI, we showed evidence that the presence of TLR4 is needed for the development of renal damage, an action that can be mediated by p38 MAPK pathways. Additional evidence of participation of these receptors is provided by deceased-donor renal grafts, in which the inevitable IRI is associated with increased expression of TLR4. Conversely, a mutation in the tlr4 gene decreases the signaling through TLR4 receptor, which may attenuate the response of kidney grafts to alarmins, hence limiting cytokine production, inflammation, and eventual organ failure.

Inflammation initiated in the kidneys can lead to the release of cytokines and chemokines to the circulation, resulting in dysfunction of distant organs such as heart and lungs. Thus, activation of renal TLR4 sets off an important signaling pathway that acts both locally and at remote organs, contributing to build up a state of systemic inflammation that considerably aggravates the clinical scenario. TLR4 blockade or inactivation constitutes a promising target for the prevention or mitigation of AKI.

Whereas TLRs can be located on the surface of cells and endosomes, NLRs are equally complex intracellular sensors that are expressed throughout the kidney and have been associated with several models of AKI. On the basis of their structure, NLRs are subdivided into three subgroups, namely, NOD1 and NOD2 or NLRP. Activation of NOD1/NOD2 sets in motion the NF-ĸB and MAPK cascades, whereas that of NLRP leads to cleavage of IL-1β and IL-18. Shigeoka et al. showed that, when subjected to renal ischemia, NOD2 KO and NOD1/NOD2 double KO mice develop less renal inflammation and tubular cell apoptosis than wild mice, being thus protected from IRI. Similar protection against tubular cell death and renal functional loss was observed in NLRP3 KO mice subjected to renal ischemia. Together, these studies lend support to the notion that the NLRP3 pathway plays a key role in the pathogenesis of inflammation and cell death in IRI-associated AKI. The participation of NLRP3 may be less prominent in other modalities of AKI, since NLRP3 KO mice were not protected against kidney damage induced by cisplatin.

Monocytes and Macrophages

In mice, circulating monocytes can be subdivided into inflammatory (Cx3CR1low, CCR2+, and Ly6Chigh) and resident (Cx3CR1high, CCR2neg, and Ly6Clow) cells. Ly6Chigh monocytes protect the kidney from damage induced by sepsis, presumably by sensing and orchestrating a response against bacterial proliferation. Ly6Clow monocytes are located at the perivascular space. Their interaction with endothelial cells decreases intercellular adhesion molecule 1 expression, thus preventing neutrophil infiltration and inflammation in IRI.

Macrophage depletion in rats protects kidney function from IRI injury, whereas blockade of the migration inhibitory factor was shown to inhibit macrophage infiltration and to ameliorate inflammation in cisplatin-induced AKI. These findings suggest that macrophages exert a central pathogenic role in this setting. However, others reported opposite results. The reason for this discrepancy is unclear but may be related to the existence of two different macrophage populations. As pointed out earlier, monocytes can differentiate into M1 or M2 macrophages, which are induced by distinct factors and acquire distinct functions. M1 macrophages appear early in the course of kidney IRI, suggesting that they contribute to initial injury, whereas the presence of M2 macrophages is predominantly seen at later phases, presumably as part of a repair process. Interestingly, transference of M1 macrophages into macrophage-depleted mice subjected to IRI rescued the adverse phenotype observed in control animals. Thus, macrophages, mainly M1, play an important pathogenic role at the onset of AKI. The existence of other macrophage subsets, their plasticity, and their role in AKI models are currently the object of intense investigation.

Neutrophils

Renal infiltration by neutrophils can be detected as early as 2 h after IRI, remaining elevated up to 72 h after the insult. Upon reaching the renal parenchyma, neutrophils are exposed to DAMPs and PAMPs, leading to activation of TLRs and NLRs and to the secretion of a number of inflammatory factors such as proteases, reactive oxygen species (ROS), and lytic enzymes. These compounds interact with the vascular endothelium, leading to vessel tumefaction and, consequently, impairing blood flow. Accordingly, neutrophil depletion exerts a protective effect in several AKI models. Recently, Raup-Konsavage et al. showed that the formation of neutrophil extracellular traps (NETs), which are instrumental for neutrophils to kill microorganisms, could be one of the mechanisms by which these cells cause tissue damage during AKI. They showed that mice KO for PAD4, an enzyme involved in NET formation, exhibited partial preservation of kidney function after IRI. However, it must be stressed that these harmful effects constitute collateral damage and that, since the primary function of neutrophils is to fight infection, their absence can be detrimental. In the model of sepsis by cecal ligation and puncture, Hoesel et al. showed that neutrophil depletion at the onset of sepsis can impair survival due to loss of antibacterial power and that a protective effect is achieved only when neutrophil depletion is performed at a later phase.

Since neutrophils appear so early in AKI, neutrophil-related proteins such as neutrophil gelatinase-associated lipocalin can be used as biomarkers of kidney damage and potential predictors of renal dysfunction and survival, as for instance in critically ill patients and in recipients of renal grafts.

Dendritic Cells

DCs are mononuclear phagocytes that, as resident cells in several organs, perform a variety of functions, acting as a bridge between innate and adaptive immunity. In the kidneys, DCs heterogeneous population, exerting several functions, such as antigen-presenting, T-cell stimulation, and production of anti-inflammatory IL-10,. Kidney DCs are located between tubules and peritubular capillaries, allowing them to interact with effector cells as well as with endothelial and epithelial cells. During AKI, kidney DCs are activated by binding of TLRs and NLRs to cell debris and other DAMPs, thus increasing the expression of costimulatory molecules and proinflammatory cytokines such as tumor necrosis factor α (TNF-α) and antigen presentation to T cells in draining lymph nodes, thus contributing to T-cell–mediated inflammation. By contrast, renal infiltration by neutrophils and monocytes, as well as tubular injury, was worsened in DC-depleted mice undergoing cisplatin-induced AKI compared to control animals, suggesting that, in this setting, the presence of DCs may exert renoprotective rather than deleterious effects. The reason for this unexpected effect is unclear and may be related to a modulatory effect of DCs on the inflammatory response. Alternatively, since DCs constitute a heterogeneous population, it is conceivable that, depending on the context, one or more subtypes exert a crucial anti-inflammatory function. Another possibility would be that monocytes and neutrophils simply occupied the niche left by the missing DCs and necrotic tubular cells. These hypotheses are currently speculative and need further investigation to be tested.

T Cells

Several lines of evidence indicate that the adaptive immune response is also involved in the pathogenesis of AKI. Animals lacking CD4+ and CD8+ T cells are protected from IRI-induced AKI, an effect associated with reduced neutrophil infiltration. CD4+ T cells can differentiate into different subsets—effector T-helper (TH) TH1/TH2/TH17 or Tregs, according to the microenvironment, to the expression of costimulatory molecules, to the presence of cytokines, and, as recently demonstrated, to variations in cell metabolism. Evaluation of specific subtypes of CD4+ T cells in IRI-induced AKI indicates that TH1 cells tend to worsen kidney damage, since mice KO for IL-12, a cytokine known to induce TH1 cells, are protected from IRI, whereas in mice KO for IL-4, cytokine known to induce TH2 cells, kidney damage is exacerbated. Moreover, T-cell–specific deletion of STAT-3, a transcription factor associated with TH17 differentiation, was renoprotective in animals subjected to IRI. IL-17 production by TH17 cells is known to increase the recruitment of neutrophils. Accordingly, IL-17 KO mice undergoing sepsis exhibited limited renal recruitment of neutrophils, associated with reduced apoptosis and less severe AKI. Consistent with these findings, higher IL-17 levels have been associated with worse outcomes in septic patients. Thus, IL-17 and TH17 cells are likely to exert a prominent role in kidney injury during sepsis. Tregs have also received considerable attention in the context of AKI. Kinsey et al. showed that depletion of Tregs worsened kidney damage during IRI-induced AKI by enhancing renal infiltration of macrophages and neutrophils and by augmenting the local levels of proinflammatory cytokines. Likewise, exacerbated kidney injury and impaired renal function after Tregs depletion were reported by Monteiro et al.. The renoprotective role of Treg was also shown in cisplatin-induced AKI. Recently, an interesting population of T cells double negative for CD4 and CD8 was described, which may represent yet another physiologic anti-inflammatory mechanism. These cells can be detected early in the course of AKI, playing a renoprotective role in an IL-10–dependent manner.

Inflammation in CKD

The mechanisms underlying the progression of CKD involve a complex interaction between hemodynamic, immunologic, metabolic, and inflammatory events. The development of inflammation, previously associated with immune dysfunction only, is currently considered a fundamental component of the pathogenesis of even non–immune-mediated CKD. Activation of DCs was shown to enhance the activity of CD8+ T cells, thus promoting glomerular injury in two different experimental models of progressive renal disease. Accordingly, inhibition of DC activation or of their interaction with CD8+ T cells preserved kidney function and decreased inflammation and fibrosis in adriamycin glomerulopathy. Other subtypes of T cells, especially TH2, may also contribute to renal damage. showed massive infiltration by CD4+ T lymphocytes in advanced human immunoglobulin A nephropathy and that depletion of CD4+ T lymphocytes prevented renal fibrosis in UUO (unilateral ureteral obstruction) mice. They also showed that the TH2/TH1 ratio increased progressively after UUO and that TH2-reconstituted mice were more prone to develop renal fibrosis than TH1-reconstituted animals. Likewise, observed an increase in TH2-related cytokines 7 days after UUO in mice, as well as an accumulation of M2 macrophages in an MyD88 pathway–dependent manner.

The role of macrophages and that of its subtypes M1 and M2 have been extensively investigated in different models of CKD. Given their properties, the notion has been established that, in various organs and experimental models of disease, M1 macrophages act in early phases of inflammation and, as this process evolves, M2 macrophages eventually predominate to promote repairing and fibrosis. In UUO mice, observed that infiltration by M1 macrophages occurs early in the course of the inflammatory process, whereas M2 macrophages accumulate only at more advanced phases, suggesting that these cells possess a resolutive, rather than profibrotic, phenotype. While this relationship between M2 macrophages and fibrosis development seems to be clear, a study using CRE-lox techniques to deplete IL-4Rα in lysozyme+ cells (macrophages and neutrophils), therefore preventing macrophages from interacting with IL-4 and IL-13—two type 2 cytokines responsible for macrophage M2 polarization —showed that, in such context, mice developed an extremely severe, and often fatal, TH1-associated inflammatory response to schistosomal infestation, whereas the reaction against a form of murine strongyloidiasis was adequate. These findings suggest that, at least in some forms of inflammation, the M2 phenotype is essential not only for tissue repair but also to prevent excessive inflammation and organ damage. Together, these findings indicate that the recruitment and differentiation of macrophages are crucial to all phases of renal injury, from triggering tissue injury to tissue repair. Any disturbance of this delicate equilibrium and/or the persistence of tissue insults will tip the balance in favor of macrophages directly involved in the development of renal inflammation( Figure 2 ).

The mechanisms leading from the initial insult to the development of inflammation and consequent renal fibrosis are incompletely understood and may involve, among others, mechanical stress to the glomerular walls due to intracapillary hypertension and/or tuft hypertrophy, direct chemical aggression to podocytes and other glomerular barrier elements, exposure of tubular cells to high protein concentrations in situations of intense proteinuria, and the participation of the renin–angiotensin–aldosterone system (RAAS) and of numerous cytokines, chemokines and growth factors. In recent years, the concept has been established that activation of innate immunity pathways, particularly that of the NF-ĸB system and of the NLPR3 inflammasome, is an important link between early events such as glomerular hypertension and advanced phenomena such as the development of renal fibrosis. This pathogenic association has been shown in several CKD models.

The expression of NLRP3, TLRs, and biglycan was shown to increase in mice subjected to UUO. Conversely, MyD88 KO mice exhibited less fibrosis after UUO. TLR2 and TLR4, as well as the NLRP3 inflammasome, seem to be activated during the development of tubulointerstitial inflammation in mice receiving dietary adenine overload, which were protected from renal fibrosis when genes coding for these molecules were deleted. Accordingly, NLRP3 activation was associated with increased inflammation in a rat model of heavy proteinuria. Recent data suggest that activation of these pathways persists throughout the development of CKD. In the 5/6 renal ablation model (Nx), the expression of innate immune-related molecules was highly expressed as early as 15 days and, for at least 60 days, after renal ablation.

The NF-ĸB cascade is another major intracellular pathway for the development of inflammation. In canonical NF-ĸB activation, the IkB kinase (IKK) degrades the inhibitory protein IkB, allowing heterodimers (e.g., p50/p65) to translocate from the cytosol to the nucleus, where they bind to the DNA and promote the transcription of a number of genes that code for proinflammatory mediators. Evidence that the NF-ĸB system is involved in the development of renal inflammation and injury has been described in a variety of clinical and experimental renal diseases, such as diabetic kidney disease, 5/6 renal ablation, adenine overload, and adriamycin nephropathy.

Although diabetic nephropathy, hypertensive nephrosclerosis, and primary glomerulopathies are currently considered the main cause of end-stage renal disease (ESRD), growing evidence indicates that AKI-associated renal inflammation may persist even after acute injury is overcome and renal function restored, giving rise to slowly progressive renal fibrosis.

As a whole, these observations indicate that AKI and CKD share a number of inflammatory pathways whereby TLRs and NLRs are activated, along with immune cells such as macrophages, DCs, and lymphocytes. The exact mechanisms by which these cells and receptors are stimulated and the full consequences of their activation are currently under intense investigation, which is expected to provide novel therapeutic strategies for these diseases. In recent years, evidence has accumulated that the gut microbiota composition may be different in those two different diseases, and may trigger and/or amplify the inflammatory response in the kidney.

The Mutualistic Relationship Between Microbes and Human Body

The human body harbors complex communities of commensal microbes, including bacteria, archaea, fungi, viruses, and protozoa. The gastrointestinal tract is one of the largest interfaces between the human body (host) and the environment. The composition and activity of gut microbiota start before birth and are influenced by a variety of factors, including birth mode, breastfeeding, age, geography, sanitation, use of antibiotics, and exercising.

Throughout the past century, evidence was amassed that microbe–host interactions modulate a large number of vital functions in the healthy human body, including host metabolism and immunity, as well as cardiovascular and brain functions. In this mutualistic relationship, the intestine provides a very favorable environment for microbes, with free access to nutrients and controlled temperature. The gut microbiota, on the other hand, is intrinsically involved in the morphogenesis and physiology of the immune system, protecting the host from potential pathogens and regulating metabolism and nutrition. Additionally, the microbial metabolism utilizes enzymes that are not encoded by the human genome and generates several biologic products essential to the host’s health, such as bile acids, choline, vitamins, and short-chain fatty acids (SCFAs).

SCFAs are the main end products of dietary carbohydrate metabolized by the gut microbiota and made available to the host. The three most abundant SCFAs, acetate, propionate, and butyrate, participate in several host vital functions. Besides being used as energy source by colonocytes, SCFAs play a key role in the maintenance of intestinal barrier integrity. Butyrate seems to regulate the expression of claudin-1 and the redistribution of zona occludens-1 and occludin, which are essential components of the tight junction assembly. SCFAs have also extraintestinal actions, including appetite regulation, glucose and lipid metabolism, and immune regulation, as shown by recent studies. Exposure of neutrophils and peripheral blood mononuclear cells to SCFAs attenuated the activation of NF-ĸB and inhibited the production of proinflammatory cytokines. SCFAs also modulate the activity of Tregs, conferring protection conditions of sustained activation of immune system. These functions rely on the ability of SCFAs to inhibit histone deacetylases and their actions through a group of G protein–coupled receptors, which are able to respond to short-, medium-, or long-chain free fatty acids. This group includes GPR41 (FFAR3), GPR43 (FFAR2), and GPR109a (HCAR2), which are responsible for the action of SCFAs in a dose-dependent manner and have been described in several cell types, such as adipocytes, neurons, immune cells, and vascular cells.

Kidney Diseases and Dysbiosis

Low-grade inflammation is a major component not only of renal diseases but is also common ground for a variety of other noncommunicable diseases, including cardiovascular disease, metabolic syndrome, neurological disorders, and allergic conditions. The development and activation of the immune system are highly dependent on microbial–host interactions, and an unbalanced relationship can lead to sustained immune activation or inappropriate suppression. Several environmental and host-related factors can disturb the microbial ecosystem to such an extent that its resilience and resistance abilities are overcome. Despite the inexistence of a core microbiome shared among healthy individuals, a common bacterial core is composed of four main phyla: Actinobacteria, Proteobacteria, Firmicutes, and Bacteroidetes. Mounting evidence indicates that compositional and functional changes in the gut microbiota (dysbiosis) are associated with intestinal and extraintestinal diseases.

Although it remains unclear whether alterations in gut microbiota caused by extrinsic factors could be the primary agent to trigger kidney injury, in the past years several studies clearly showed that impaired kidney function contributes to gut dysbiosis, which in turn aggravates kidney injury. The importance of gut microbiota in kidney diseases was demonstrated by, who showed that germ-free mice are more susceptible to kidney injury, whereas reintroduction of a gut microbiota conferred protection against the disease. Germ-free mice exhibited an abnormal high number of natural killer T cells and lower IL-4 levels in the kidneys, which were more susceptible to ischemia–reperfusion damage.

Growing evidence indicates that gut dysbiosis causes gut inflammation and impairs intestinal barrier integrity, resulting in activation of the NF-ĸB pathway and, ultimately, systemic inflammation. Disruption of intestinal barrier enables the translocation of bacterial endotoxins, such as lipopolysaccharide (LPS), leading to activation of immune cells at the lamina propria and to enhanced secretion of proinflammatory cytokines. Of note, endotoxemia is correlated with the risk of mortality in CKD patients. Microbial dysbiosis can also contribute to kidney failure through the accumulation of bacterial-produced uremic toxins, such as indoxyl sulfate (IS), p-cresol sulfate, and trimethylamine-N-oxide (TMAO). Using germ-free technology, demonstrated that the gut microbiome strongly influences the levels of several protein-bound uremic toxins. Under healthy conditions, these toxins are partially eliminated with the feces, whereas whatever amount absorbed by the intestine is excreted by the kidneys. Therefore, impairment of kidney function can lead to the retention of uremic toxins that originated in the gut. Several studies have observed high levels of these toxins in patients with kidney failure. Increased levels of p-cresol sulfate were found in patients with mild to moderate CKD and were associated with low estimated glomerular filtration rate. Likewise, circulating TMAO levels rise as kidney function declines in CKD patients and correlate with lower long-term survival rates. Some studies reported adverse effects of uremic toxins on the kidney. These toxins instigate inflammation by increasing ROS production and the levels of proinflammatory cytokines ( Figure 2 ). In addition, they can promote renal fibrosis through reduction of klotho expression and cell senescence.

It is noteworthy that, in turn, CKD can affect the status of gut microbiota, thus contributing to dysbiosis. Growing evidence has shown significant changes in the gut microbiota of CKD patients in terms of individual species. Kidney diseases lead to metabolic acidosis, volume overload, recurrent use of antibiotics, prolonged colonic transit time, intestinal wall edema, and reduction of dietary fiber intake, which can not only alter the intestinal permeability, but may cause an imbalance in gut microbiota. Moreover, profound changes can be induced by uremia per se. observed significant alterations in the abundance of 175 bacterial operational taxonomic units in nephrectomized rats, indicating that the effect of uremia is independent from interindividual variations, comorbid conditions, and dietary and medical interventions. Furthermore, ESRD patients showed expansion of bacterial families possessing enzymes that produce uremic toxins in detriment of those expressing enzymes that degrade fibers and generate SCFAs. This adverse scenario is further aggravated by the medical recommendation to reduce the intake of fruits and vegetables to avoid hyperkalemia. Because fiber-rich foods are the major source of resistance starch used to generate SCFAs, one can speculate that the consequent reduction in the production of SCFAs may contribute to kidney damage. Indeed, low intake of fiber forces a switch in the gut microbiota metabolism leading to decreased production of SCFAs and to the generation of harmful metabolites. A potential additional adverse effect of fiber restriction was pointed out in an elegant experimental study showing that, in a scenario of dietary fiber deficiency, gut microbiota resorts to host-secreted mucus glycoproteins as a nutrient source, resulting in a thinner colonic mucus layer, which could contribute to enhanced pathogen susceptibility, endotoxemia, and, ultimately, systemic inflammation.

Gut Microbiota–Based Therapies

In an elegant study, reported a high resemblance between the fecal metabolite profiles of CKD patients and those of their household contacts on the same diet, after adjustment for age, gender, body mass index, and the presence of diabetes mellitus. CKD-related changes in the human colonic microbial metabolism were largely attributable to dietary restrictions and, to a lesser extent, to loss of renal function. Thus, the plasticity of gut microbiota in response to environmental factors offers a potential avenue for therapeutic interventions aimed at slowing the progression of kidney disease and reducing cardiovascular risk factors in these patients.

Dietary Fiber and Prebiotics

Dietary fiber has been defined as edible carbohydrate polymers (with three or more monomeric units), which are not enzymatically digested, hydrolyzed, or absorbed in the small intestine. Consumption of a fiber-rich diet has been linked to lower risk of allergy, depression, and cardiovascular disease. However, reduction in the intake of dietary fiber, present mostly in fruits and vegetables, is usually recommended to patients with advanced CKD in order to avoid the accumulation of potassium. Unfortunately, as mentioned earlier, fiber deprivation leads to a reduction of intestinal mucus barrier due to the overgrowth of mucin-degrading bacteria. Furthermore, mucus degradation may enhance pathogen susceptibility and bacteria translocation and exacerbate local and systemic inflammation status. This dilemma can be addressed by a novel approach based on the administration of substances or living organisms aimed at modifying the intestinal bioma. This goal can be achieved by so-called prebiotics, probiotics, symbiotics, or postbiotics.

Prebiotics

The use of prebiotics, defined as nondigestible ingredients capable of stimulating the growth and/or activity of health-promoting bacteria, is a widely known strategy to alter the gut microbiota. In both healthy and pathological conditions, prebiotics favor the growth of beneficial bacteria (e.g., bifidobacteria and lactobacilli), while suppressing potentially pathogenic microorganisms such as clostridia and enterobacteria. Inulin supplementation induced a selective increase of “healthy” gut microbiota components, including bifidobacteria, in a randomized double-blind, placebo-controlled, crossover trial. In a similar study involving obese women, inulin treatment afforded equally beneficial results. Shifts in the gut microbiota composition induced by prebiotics are dependent on their carbon structure and on the microbial enzymatic ability to process them. Recent data showed that, in patients with type 2 diabetes, dietary fiber intake promoted selective growth of a group of SCFA-producing strains, while most other potential SCFA producers were inhibited or remained unchanged. In addition, the growth of producers of harmful metabolites was diminished. These changes were accompanied by clinical benefits such as lower hemoglobin A1c levels.

Besides their potential effect on the generation of SCFAs, plant-based diets exert other effects on metabolites produced by the gut microbiota. For instance, they contain less TMAO precursors compared to an animal-based diet. Experimental data showed that the consumption of amylose-enriched diet retards the progression of kidney damage through the attenuation of oxidative stress, inflammation, and fibrosis. Additionally, human interventional studies showed that fiber-rich diets and prebiotics ameliorated metabolic disorders, reduced uremic toxins, and delayed the decline in glomerular filtration rate. Moreover, epidemiological studies indicated that high total fiber intake is associated with lower risk of inflammation and mortality in CKD. observed low serum concentrations of IS and p-cresol in hemodialysis patients under dietary prebiotic oligofructose-enriched inulin supplementation. Likewise, the intake of resistant starch improved renal function in CKD and significantly decreased serum concentrations of uremic toxins in hemodialysis patients. Extrarenal benefits have also been observed, such as weight loss and improved metabolism of glucose and lipids, lending further support to the therapeutic use of prebiotics.

Probiotics

The Food and Agriculture Organization of the United Nations and the World Health Organization define probiotics as “live microorganisms that when administered in adequate amounts confer a health benefit on the host”. Probiotics consist of living bacteria (mostly bifidobacteria and lactobacilli species) that can be added to food, drugs, and dietary supplements. As with prebiotics, oral administration of live microorganisms does not significantly change the composition of the indigenous gut microbiota in healthy adults. However, benefits of probiotic therapy have been extensively observed in several pathological scenarios, probably through the generation of bioactive metabolites and immunomodulation.

Animal studies support the beneficial effects of probiotic therapy in CKD. Administration of Bacillus pasteurii and Lactobacillus sporogenes reduced blood urea nitrogen (BUN) levels and prolonged the life span of uremic rats. Treatment with the urease-positive bacterium Sprosarcina pasteurii showed similar benefits by removing urea from the gut. Similar to these findings, treatment of rats with 5/6 renal ablation with Lactobacillus acidophilus attenuated inflammation by reducing the serum levels of uremic toxins, such as IS and p-cresyl sulfate, and inflammatory mediators (LPS, C-reactive protein, and IL-6). At the same time, this treatment ameliorated urinary protein excretion and reduced the glomerulosclerosis index.

Clinical studies have also demonstrated that probiotic supplementation improves renal function. Simenhoff et al. first reported that oral administration of L. acidophilus lowered serum levels of the potential uremic toxin dimethylamine and nitrosodimethylamine in hemodialysis patients. Likewise, other studies have observed reduced levels of homocysteine and IS in hemodialysis patients under oral treatment with Bifidobacterium longum. A 6-month supplementation with a blend of L. acidophilus, B. longum, and Streptococcus thermophilus ameliorated renal function and the quality of life of 46 patients in stage III or IV of CKD.

Recently, genetically engineered bacteria have been used to reduce renal inflammation and proinflammatory mediators in intestinal diseases. Bacteria can be genetically modified to sense, kill, or restrain specific pathogens or to produce biomolecules, such as human hormones, ILs, and antibodies within specific organs or tissues. Oral administration of Lactococcus lactis resulted in local delivery of anti-TNF nanobodies at the colon and significantly reduced inflammation in mice with dextran sulfate sodium–induced chronic colitis. Beneficial effects were also reported using a L. lactis strain engineered to secrete the anti-inflammatory cytokine IL-10 in Crohn disease. This cutting-edge therapeutic approach has also been applied in extraintestinal diseases. A strategy using a L. lactis strain engineered to secrete proinsulin and IL-10 induced autoantigen-specific long-term tolerance, allowing reversal of established autoimmune diabetes in mice. Engineered bacteria have also been used to emulate urease-producing bacteria. successfully used genetically modified Escherichia coli DH5 to remove urea and ammonia, hence lowering BUN in uremic rats.

Symbiotics

Combined therapies using prebiotics and probiotics (symbiotics) have been explored in an attempt to alleviate both the toxic effects of uremia and the gut dysbiosis associated with CKD. A randomized double-blind pilot study of CKD stages IV and V reported that a combination of high-molecular-weight inulin, fructo-oligosaccharides, galacto-oligosaccharides, lactobacilli, bifidobacteria, and streptococci altered the stool microbiome, particularly with enrichment of Bifidobacterium and depletion of Ruminococcaceae, and reduced plasma concentrations of p-cresol. Likewise, 4-week treatment with the commercially available symbiotic Probinul-neutro® decreased p-cresol levels in patients with CKD stages III and IV. Additionally, a therapeutic combination of galacto-oligosaccharides and Lactobacillus casei strain Shirota and Bifidobacterium breve strain Yakult led to normalization of bowel habits and a decrease of serum p-cresol levels in hemodialysis patients.

Despite the benefits observed in a variety of diseases, the success of probiotic-based therapies seems to depend heavily on the pathological condition and on the selected microbial species chosen. For example, treatment with E. coli Nissle 1917 is recommended in cases of constipation in adults, while Bacillus coagulans seems suitable to treat antibiotic-associated diarrhea. Further investigation is needed to ensure the safety and the effectiveness of probiotics in different populations and diseases.

Postbiotics

The use of postbiotics, also known as metabiotics, has been recently proposed as an adjunctive or alternative therapeutic approach for a healthier gut homeostasis and mucosal immune system. The term postbiotic has been coined to designate products from nonviable bacteria or metabolic byproducts from probiotic microorganisms, such as vitamins, SCFAs, cell surface proteins, and enzymes that can affect positively the gut microbiome and the host. According to, postbiotics have favorable absorption, metabolism, distribution, and excretion properties, which could indicate a high capacity to elicit favorable biological responses in different organs in the host. Although the postbiotic therapy has never been applied in CKD, it is noteworthy that many commensal bacteria produce SCFAs, which, as pointed out earlier, exert a number of beneficial effects. Regarding kidney diseases, reported that treatment with SCFAs reduces kidney injury induced by ischemia–reperfusion by protecting the renal tissue against inflammation and oxidative stress and by increasing autophagy, reducing apoptosis, and improving mitochondrial biogenesis.

Fecal Microbiota Transplantation

Fecal microbiota transplantation (FMT) refers to the introduction of indigenous intestinal microbes from a healthy donor using capsules or colonoscopy into a dysbiotic gut, aiming to restore the microbial community. FMT differs from probiotic therapy in that the donor material is a mixture of undefined microorganisms, including bacteria, yeasts, parasites, and viruses. Although the first reports date back over 1,700 years, FMT is a relatively new therapy for recurrent or refractory Clostridium difficile infection (CDI), being moderately recommended as an alternative treatment for a third recurrent CDI after a pulsed vancomycin regimen. The mechanism of action of FMT is unclear. The high rates of resolution of CDI may be due to the infusion of large amounts of bacteria to the gut and/or a variety of metabolites present in the donor sample. FMT has been used in conditions other than CDI, such as metabolic syndrome, autism, and multiple sclerosis, although the results with irritable bowel syndrome were disappointing. Clinical studies focusing on the possible beneficial effects of FMT on CKD are lacking. Only anecdotal cases of recurrent infections in a patient with ESRD and in a kidney graft recipient have been reported.

Despite their positive effects on the levels of uric acid and BUN, no prebiotic-, probiotic-, or symbiotic-based approaches have been shown to normalize the levels of uremic toxins. Moreover, the long-term impact of these therapies on CKD progression remains unknown due to a number of limitations, such as small sample size and short duration of studies. Larger clinical studies are needed in order to ascertain the possible application of these innovative strategies in the treatment of CKD.

Repurposed Drugs to Target Renal Inflammation

Recent studies have shown unexpected beneficial effects for repurposed or emerging drugs in the context of AKI and CKD. Several drugs and compounds used to modulate inflammation and immune response in experimental and/or human conditions, such as gout, hypertension, autoimmune diseases, cancer, and organ transplantation, may exert renoprotection by limiting oxidative stress and inflammation. These drugs may exert anti-inflammatory effects by acting on one or more pathogenic pathways such as the RAAS, the innate immune response, and/or the adaptive immunity.

RAAS Inhibition in Kidney Inflammation

RAAS inhibition is one of the most widely used therapies for the control of hypertension, a leading risk factor for CKD, along with diabetes mellitus. In addition, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are extensively used to prevent or delay the progression of established CKD. Evidence amassed in the past three decades shows that, besides their hemodynamic effects, ACEIs and ARBs directly influence the immune response. Angiotensin II stimulates the expression of inflammatory mediators such as cytokines, chemokines, growth factors, and adhesion molecules in renal parenchymal and immune cells, as well as splenic lymphocyte proliferation. Moreover, intrarenal angiotensin II production may participate in local inflammation, whereas RAAS blockade was shown to provide hemodynamic-independent renoprotection. An extremely high dose of losartan ameliorated renal injury and promoted regression of hypertension and albuminuria in the Nx model by reducing the renal macrophage infiltration and the interstitial angiotensin II expression, rather than by lowering intraglomerular pressure. Losartan also exerted effective renoprotection and anti-inflammatory effects in the streptozotocin diabetes model. These beneficial effects were markedly amplified when losartan was administered along with hydrochlorothiazide, even when the combined therapy was started after renal injury was already advanced. The renoprotective effect of RAAS inhibitors may be partially mediated by limiting activation of the NF-κB pathway ( Figure 2 ), known to be activated by angiotensin II in experimental CKD.

Few studies have investigated the anti‐inflammatory potential of RAAS-blocking agents in humans. The use of ACEIs is associated with lower plasma TNF-α and C‐reactive protein levels in patients with advanced CKD. A comparative study showed that the ACEI ramipril and, especially, the ARB valsartan lowered the IL-6 levels in hemodialysis patients. In addition, losartan treatment prevented the differentiation of monocytes into proinflammatory CD14+CD16+ cells and of oxidative stress–related inflammation in hemodialysis patients. However, other studies failed to show blood pressure–independent anti-inflammatory effects of ARBs in hemodialysis patients. Thus, further studies are needed to clarify the effect of the RAAS blockers on human renal inflammation.

Allopurinol Inhibits Activation of the Renal NLRP3 Inflammasome

Hyperuricemia is present in 20% to 35% of patients with CKD. Although hyperuricemia is usually asymptomatic, urate crystals may accumulate in tissues such as articular synovium, causing joint inflammation and the symptoms usually associated with gout. Whether hyperuricemia is a real risk factor or just a biomarker of renal and cardiovascular injury is presently unclear. However, recent studies suggest that reducing circulating uric acid slows the progression of CKD. Allopurinol, a prodrug of oxipurinol, a xanthine oxidase inhibitor, is widely employed in the treatment of hyperuricemia. Besides reducing uric acid production, xanthine oxidase inhibition by allopurinol also diminishes ROS production, thus exerting antioxidant and anti-inflammatory effects. It is noteworthy that both crystals of uric acid and ROS can activate the NLRP3 inflammasome. Furthermore, emerging evidence indicates that soluble uric acid is equally capable of activating this inflammasome complex in renal cells and that allopurinol inhibits this process ( Figure 2 ). Accordingly, NLRP3 inhibition following allopurinol treatment ameliorated renal inflammation and injury in experimental diabetic kidney disease. In the UUO model, allopurinol reduced the renal content of soluble uric acid and inhibited NLRP3 activation, preventing the progression of proteinuria, as well as renal fibrosis and inflammation. In a recent study of the Nx model, we showed that allopurinol reduced soluble renal uric acid and oxidative stress, thus reducing NLRP3 activation and IL-1β levels, as well as tubulointerstitial inflammation and fibrosis.

Inhibition of uric acid synthesis can also exert beneficial effects in human CKD. In a 2-year randomized controlled trial, Goicoechea et al. showed that treatment with allopurinol prevented the progressive decline in glomerular filtration rate in patients with CKD of various etiologies. In a post hoc analysis of these patients 5 years later, it was shown that long-term treatment with allopurinol not only slowed CKD progression, but also reduced cardiovascular risk. Similar findings were obtained in a 3-year randomized parallel-controlled study of type 2 diabetic patients with asymptomatic hyperuricemia. As a whole, these experimental studies and randomized trials reinforce the view that allopurinol can contribute to slow the progression of renal disease.

NF-κB Inhibition Slows CKD Progression

Inhibition of NF-κB, a major innate immunity pathway, has been proposed as a strategy to reduce inflammation and retard or detain the progression of a number of renal diseases. NF-κB activation can be blocked by preventing IkB degradation. The antioxidant compound pyrrolidine dithiocarbamate (PDTC) inhibits IKK, thus preventing NF-ĸB activation ( Figure 2 ). In NX model, PDTC treatment inhibited activation of renal NF-ĸB and, ameliorated glomerular and interstitial injury in the Nx model. In rats receiving adenine overload, PDTC strongly attenuated renal interstitial fibrosis. In both studies, PDTC markedly reduced renal infiltration by macrophages, underlining its anti-inflammatory effect. Accordingly, in an experimental model of CKD by type 1 diabetes, renal NF-ĸB was activated in association with increased MCP-1 gene expression and macrophage infiltration as early as 1 month after induction of diabetes mellitus. PDTC reduced renal inflammation at this time point, although its long-term effect on kidney injury was not assessed.

Interestingly, rats treated with PDTC during lactation developed hypertension as adults, in association with early activation of the RAAS and upregulation of sodium transporters, without renal structural damage or functional impairment, in contrast with the severe renal damage caused by neonatal losartan. This finding suggests that the NF-κB system is needed during nephrogenesis for adequate renal control of blood pressure in adult life, but not for nephrogenesis. In a subsequent study, rats that had received neonatal PDTC were subjected to uninephrectomy and salt overload in adult life. These animals exhibited marked NF-ĸB activation and developed severe inflammation and injury to glomerular, interstitial, and arterioles. Curiously, treatment of adult rats with losartan inhibited renal NF-κB and attenuated renal injury/inflammation.

Parthenolide is a sesquiterpene lactone that occurs naturally in some plants and has been proposed as an NF-ĸB inhibitor ( Figure 2 ). However, few data are available regarding the effect of parthenolide in kidney diseases. In cisplatin-induced renal damage, parthenolide reduced renal injury and inflammation. In the UUO model, parthenolide reduced renal monocyte/macrophage infiltration and attenuated renal injury. Although some drugs currently employed in the treatment of kidney diseases possess anti-inflammatory effects and can inhibit renal NF-κB activation, no specific NF-κB inhibitor is available for human use. Systemic inhibition of NF-κB may cause substantial adverse effects, since NF-κB is required for adequate nephrogenesis, immune responses, and cell survival. Thus, understanding the mechanisms underlying NF-κB activation and/or inhibition in renal diseases is crucial for the development of more specific regulators, allowing this system to become an important therapeutic target in the quest to prevent the progression of human kidney disease.

Concluding Remarks

Renal inflammation is central to the development of both AKI and CKD, as well as to the transition of AKI to CKD. Activation of major pathways of innate immunity, such as the NF-ĸB system and the NLRP3 inflammasome, is one of the main factors triggering renal inflammation in both AKI and CKD. The role of the gut microbiota in the pathogenesis of inflammation and its dynamic relationship with renal disease have been unraveled in recent years. New avenues of investigation and new therapeutic perspectives have been opened with the development of suitable NLRP3 and NF-ĸB inhibitors, as well as of strategies centered on the manipulation of the gut microbiota. Additional therapeutic possibilities are provided by the repurposing of old drugs such as allopurinol. New clinical trials will establish the value of these novel approaches for a better comprehension of the mechanisms underlying the pathogenesis of AKI and CKD and for the development of innovative therapeutic strategies in the management of these serious conditions.

Author Contributions

VA-O, OF-N and IW conceived the figures and wrote the manuscript. RZ and NC conceived the idea, wrote and supervisioned the manuscript.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 258

  1. 1.

    Aagaard K. Ma J. Antony K. M. Ganu R. Petrosino J. Versalovic J. (2014 ). The placenta harbors a unique microbiome. Sci. Translatl. Med. 6 (237), 237ra65.

    Not in our library10.1126/scitranslmed.3008599

  2. 2.

    Adijiang A. Shimizu H. Higuchi Y. Nishijima F. Niwa T. (2011 ). Indoxyl sulfate reduces klotho expression and promotes senescence in the kidneys of hypertensive rats. J. Renal Nutr. 21 (1), 105–109.

    Not in our library10.1053/j.jrn.2010.10.020

  3. 3.

    Aguilar-Toala J. E. Garcia-Valera H. Garcia H. S. Mata-Haro V. Gonzalez-Cordova A. F. Vallejo-Cordoba B. (2018 ). Postbiotics: an evolving term within the functional foods field. Trends Food Sci. Technol. 75, 105–114.

    Not in our library10.1016/j.tifs.2018.03.009

  4. 4.

    Aliasgharzadeh A. Dehghan P. Gargari B. P. Asghari-Jafarabadi M. (2015 ). Resistant dextrin, as a prebiotic, improves insulin resistance and inflammation in women with type 2 diabetes: a randomised controlled clinical trial. Br. J. Nutr. 113 (2), 321–330.

    Not in our library10.1017/s0007114514003675

  5. 5.

    Allam R. Scherbaum C. R. Darisipudi M. N. Mulay S. R. Hagele H. Lichtnekert J. (2012 ). Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4. J. Am. Soc. Nephrol. 23 (8), 1375–1388.

    Not in our library10.1681/asn.2011111077

  6. 6.

    Amano M. T. Castoldi A. Andrade-Oliveira V. Latancia M. T. Terra F. F. Correa-Costa M. (2018 ). The lack of PI3Kgamma favors M1 macrophage polarization and does not prevent kidney diseases progression. Int. Immunopharmacol. 64, 151–161.

    Not in our library10.1016/j.intimp.2018.08.020

  7. 7.

    Anders H. J. Andersen K. Stecher B. (2013 ). The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int. 83 (6), 1010–1016.

    Not in our library10.1038/ki.2012.440

  8. 8.

    Andersen K. Kesper M. S. Marschner J. A. Konrad L. Ryu M. Kumar Vr S. (2017 ). Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for CKD-related systemic inflammation. J. Am. Soc. Nephrol. 28 (1), 76–83.

    Not in our library10.1681/asn.2015111285

  9. 9.

    Andrade-Oliveira V. Campos E. F. Goncalves-Primo A. Grenzi P. C. Medina-Pestana J. O. Tedesco-Silva H. (2012 ). TLR4 mRNA levels as tools to estimate risk for early posttransplantation kidney graft dysfunction. Transplantation 94 (6), 589–595.

    Not in our library10.1097/tp.0b013e31825db680

  10. 10.

    Andrade-Oliveira V. Amano M. T. Correa-Costa M. Castoldi A. Felizardo R. J. de Almeida D. C. (2015 ). Gut bacteria products prevent aki induced by ischemia–reperfusion. J. Am. Soc. Nephrol. 26 (8), 1877–1888.

    Not in our library10.1681/asn.2014030288

  11. 11.

    Andrade-Silva M. Cenedeze M. A. Perandini L. A. Felizardo R. J. F. Watanabe I. K. M. Agudelo J. S. H. (2018 ). TLR2 and TLR4 play opposite role in autophagy associated with cisplatin-induced acute kidney injury. Clin. Sci. (Lond) 132 (16), 1725–1739.

    Not in our library10.1042/cs20170262

  12. 12.

    Arias S. C. Valente C. P. Machado F. G. Fanelli C. Origassa C. S. de Brito T. (2013 ). Regression of albuminuria and hypertension and arrest of severe renal injury by a losartan–hydrochlorothiazide association in a model of very advanced nephropathy. PLoS One 8 (2), e56215.

    Not in our library10.1371/journal.pone.0056215

  13. 13.

    Arumugam M. Raes J. Pelletier E. Le Paslier D. Yamada T. Mende D. R. (2011 ). Enterotypes of the human gut microbiome. Nature. 473 (7346), 174–180.

    Not in our library10.1038/nature09944

  14. 14.

    Ávila V. F. Foresto-Neto O. Arias S. C. A. Faustino V. D. Malheiros D. M. A. C. Camara N. O. S. (2019 ). Pathogenic role of angiotensin II and the NF-κB system in a model of malignant hypertensive nephrosclerosis. Hypertens. Res. 42, 779–789.

    Not in our library10.1038/s41440-019-0226-6

  15. 15.

    Awad A. S. Rouse M. Huang L. Vergis A. L. Reutershan J. Cathro H. P. (2009 ). Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury. Kidney Int. 75 (7), 689–698.

    Not in our library10.1038/ki.2008.648

  16. 16.

    Bakris G. L. Lass N. Gaber A. O. Jones J. D. Burnett J. C. (1990 ). Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am. J. Physiol. 258 (1 Pt 2), F115–F120.

    Not in our library10.1152/ajprenal.1990.258.1.f115

  17. 17.

    Bammens B. Verbeke K. Vanrenterghem Y. Evenepoel P. (2003 ). Evidence for impaired assimilation of protein in chronic renal failure. Kidney Int. 64 (6), 2196–2203.

    Not in our library10.1046/j.1523-1755.2003.00314.x

  18. 18.

    Biehl L. M. Cruz Aguilar R. Farowski F. Hahn W. Nowag A. Wisplinghoff H. (2018 ). Fecal microbiota transplantation in a kidney transplant recipient with recurrent urinary tract infection. Infection 46 (6), 871–874.

    Not in our library10.1007/s15010-018-1190-9

  19. 19.

    Bindels L. B. Delzenne N. M. Cani P. D. Walter J. (2015 ). Towards a more comprehensive concept for prebiotics. Nat. Rev. Gastroenterol. Hepatol. 12 (5), 303–310.

    Not in our library10.1038/nrgastro.2015.47

  20. 20.

    Braat H. Rottiers P. Hommes D. W. Huyghebaert N. Remaut E. Remon J. P. (2006 ). A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clinical Gastroenterol. Hepatol. 4 (6), 754–759.

    Not in our library10.1016/j.cgh.2006.03.028

  21. 21.

    Braga T. T. Correa-Costa M. Guise Y. F. Castoldi A. de Oliveira C. D. Hyane M. I. (2012 ). MyD88 signaling pathway is involved in renal fibrosis by favoring a TH2 immune response and activating alternative M2 macrophages. Mol Med. 10 2418, 1231–1239.

    Not in our library10.2119/molmed.2012.00131

  22. 22.

    Braga T. T. Correa-Costa M. Azevedo H. Silva R. C. Cruz M. C. Almeida M. E. (2016 ). Early infiltration of p40IL12(+)CCR7(+)CD11b(+) cells is critical for fibrosis development. Immun. Inflamm. Dis. 4 (3), 300–314.

    Not in our library10.1002/iid3.114

  23. 23.
    Soluble Uric Acid Activates the NLRP3 Inflammasome · 2017
    No notice
  24. 24.

    Braga T. T. Moura I. C. Lepique A. P. Camara N. O. S. (2017 a). Editorial: macrophages role in integrating tissue signals and biological processes in chronic inflammation and fibrosis. Front. Immunol. 8, 845.

    Not in our library10.3389/fimmu.2017.00845

  25. 25.

    Braga T. T. Correa-Costa M. Silva R. C. Cruz M. C. Hiyane M. I. da Silva J. S. (2018 ). CCR2 contributes to the recruitment of monocytes and leads to kidney inflammation and fibrosis development. Inflammopharmacology 26 (2), 403–411.

    Not in our library10.1007/s10787-017-0317-4

  26. 26.

    Brenner B. M. Cooper M. E. de Zeeuw D. Keane W. F. Mitch W. E. Parving H. H. (2001 ). Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345 (12), 861–869.

    Not in our library10.1056/nejmoa011161

  27. 27.

    Brinkmann V. Reichard U. Goosmann C. Fauler B. Uhlemann Y. Weiss D. S. (2004 ). Neutrophil extracellular traps kill bacteria. Science 303 (5663), 1532–1535.

    Not in our library10.1126/science.1092385

  28. 28.

    Brown A. J. Goldsworthy S. M. Barnes A. A. Eilert M. M. Tcheang L. Daniels D. (2003 ). The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 278 (13), 11312–11319.

    Not in our library10.1074/jbc.m211609200

  29. 29.

    Campanholle G. Landgraf R. G. Goncalves G. M. Paiva V. N. Martins J. O. Wang P. H. (2010 ). Lung inflammation is induced by renal ischemia and reperfusion injury as part of the systemic inflammatory syndrome. Inflammation Res. 59 (10), 861–869.

    Not in our library10.1007/s00011-010-0198-0

  30. 30.

    Camps J. Garcia-Heredia A. (2014 ). Introduction: oxidation and inflammation, a molecular link between non-communicable diseases. Adv. Exp. Med. Biol. 824, 1–4.

    Not in our library10.1007/978-3-319-07320-0_1

  31. 31.

    Canale D. Rodrigues M. V. Ferreira D. N. Machado F. G. Veras M. M. Malheiros D. M. (2011 ). Programmed hypertension in rats treated with a NF-κB inhibitor during nephrogenesis: renal mechanisms. Hypertens. Res. 34 (6), 693–700.

    Not in our library10.1038/hr.2011.4

  32. 32.

    Cani P. D. Neyrinck A. M. Fava F. Knauf C. Burcelin R. G. Tuohy K. M. (2007 ). Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50 (11), 2374–2383.

    Not in our library10.1007/s00125-007-0791-0

  33. 33.

    Cao Q. Lu J. Li Q. Wang C. Wang X. M. Lee V. W. (2016 ). CD103+ dendritic cells elicit CD8+ T cell responses to accelerate kidney injury in adriamycin nephropathy. J. Am. Soc. Nephrol. 27 (5), 1344–1360.

    Not in our library10.1681/asn.2015030229

  34. 34.

    Carneiro L. A. Magalhaes J. G. Tattoli I. Philpott D. J. Travassos L. H. (2008 ). Nod-like proteins in inflammation and disease. J. Pathol. 214 (2), 136–148.

    Not in our library10.1002/path.2271

  35. 35.
    TLR2, TLR4 and the MYD88 Signaling Pathway Are Crucial for Neutrophil Migration in Acute Kidney Injury Induced by Sepsis · 2012
    No notice
  36. 36.

    Chang P. V. Hao L. Offermanns S. Medzhitov R. (2014 ). The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc. Natl. Acad. Sci. U. S. A. 111 (6), 2247–2252.

    Not in our library10.1073/pnas.1322269111

  37. 37.
    Faecal microbiota transplantation: Where did it start? What have studies taught us? Where is it going? · 2017
    Not checked
  38. 38.

    Chawla L. S. Kimmel P. L. (2012 ). Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int. 82 (5), 516–524.

    Not in our library10.1038/ki.2012.208

  39. 39.

    Chawla L. S. Eggers P. W. Star R. A. Kimmel P. L. (2014 ). Acute kidney injury and chronic kidney disease as interconnected syndromes. N. Eng. J. Med. 371 (1), 58–66.

    Not in our library10.1056/nejmra1214243

  40. 40.

    Chen C. B. Liu L. S. Zhou J. Wang X. P. Han M. Jiao X. Y. (2017 ). Up-regulation of HMGB1 exacerbates renal ischemia–reperfusion injury by stimulating inflammatory and immune responses through the TLR4 signaling pathway in mice. Cell Physiol. Biochem. 41 (6), 2447–2460.

    Not in our library10.1159/000475914

  41. 41.

    Chiavaroli L. Mirrahimi A. Sievenpiper J. L. Jenkins D. J. Darling P. B. (2015 ). Dietary fiber effects in chronic kidney disease: a systematic review and meta-analysis of controlled feeding trials. Eur. J. Clin. Nutr. 69 (7), 761–768.

    Not in our library10.1038/ejcn.2014.237

  42. 42.

    Chmielewska A. Szajewska H. (2010 ). Systematic review of randomised controlled trials: probiotics for functional constipation. World J. Gastroenterol. 16 (1), 69–75.

    Not in our library10.3748/wjg.v16.i1.69

  43. 43.

    Clarke S. F. Murphy E. F. O’Sullivan O. Lucey A. J. Humphreys M. Hogan A. (2014 ). Exercise and associated dietary extremes impact on gut microbial diversity. Gut 63 (12), 1913–1920.

    Not in our library10.1136/gutjnl-2013-306541

  44. 44.

    Correa-Costa M. Braga T. T. Semedo P. Hayashida C. Y. Bechara L. R. Elias R. M. (2011 ). Pivotal role of Toll-like receptors 2 and 4, its adaptor molecule MyD88, and inflammasome complex in experimental tubule-interstitial nephritis. PloS one 6 (12), e29004.

    Not in our library10.1371/journal.pone.0029004

  45. 45.
    Transcriptome analysis of renal ischemia/reperfusion injury and its modulation by ischemic pre-conditioning or hemin treatment. · 2012
    Not checked
  46. 46.

    Correa-Costa M. Braga T. T. Felizardo R. J. Andrade-Oliveira V. Perez K. R. Cuccovia I. M. (2014 ). Macrophage trafficking as key mediator of adenine-induced kidney injury. Mediators Inflamm. 2014, 291024.

    Not in our library10.1155/2014/291024

  47. 47.

    de Paiva V. N. Monteiro R. M. Marques Vde P. Cenedeze M. A. Teixeira Vde P. dos Reis M. A. (2009 ). Critical involvement of TH1-related cytokines in renal injuries induced by ischemia and reperfusion. Int. Immunopharmacol. 9 (6), 668–672.

    Not in our library10.1016/j.intimp.2008.11.012

  48. 48.

    den Besten G. Bleeker A. Gerding A. van Eunen K. Havinga R. van Dijk T. H. (2015 ). Short-chain fatty acids protect against high-fat diet–induced obesity via a PPARgamma-dependent switch from lipogenesis to fat oxidation. Diabetes. 64 (7), 2398–2408.

    Not in our library10.2337/db14-1213

  49. 49.

    Deng B. Lin Y. Ma S. Zheng Y. Yang X. Li B. (2017 ). The leukotriene B4-leukotriene B4 receptor axis promotes cisplatin-induced acute kidney injury by modulating neutrophil recruitment. Kidney Int. 92 (1), 89–100.

    Not in our library10.1016/j.kint.2017.01.009

  50. 50.

    Desai M. S. Seekatz A. M. Koropatkin N. M. Kamada N. Hickey C. A. Wolter M. (2016 ). A dietary fiber–deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 167 (5), 1339–53 e21.

    Not in our library10.1016/j.cell.2016.10.043

  51. 51.

    Dewulf E. M. Cani P. D. Claus S. P. Fuentes S. Puylaert P. G. Neyrinck A. M. (2013 ). Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 62 (8), 1112–1121.

    Not in our library10.1136/gutjnl-2012-303304

  52. 52.

    Dominguez-Bello M. G. Costello E. K. Contreras M. Magris M. Hidalgo G. Fierer N. (2010 ). Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc. Natl. Acad. Sci. U. S. A. 107 (26), 11971–11975.

    Not in our library10.1073/pnas.1002601107

  53. 53.

    Dong X. Swaminathan S. Bachman L. A. Croatt A. J. Nath K. A. Griffin M. D. (2007 ). Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia–reperfusion injury. Kidney Int. 71 (7), 619–628.

    Not in our library10.1038/sj.ki.5002132

  54. 54.

    Duncan S. H. Belenguer A. Holtrop G. Johnstone A. M. Flint H. J. Lobley G. E. (2007 ). Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl. Environ. Microbiol. 73 (4), 1073–1078.

    Not in our library10.1128/aem.02340-06

  55. 55.

    Esteban V. Ruperez M. Vita J. R. López E. S. Mezzano S. Plaza J. J. (2003 ). Effect of simultaneous blockade of AT1 and AT2 receptors on the NFkappaB pathway and renal inflammatory response. Kidney Int Suppl. 64 (86), S33–S38.

    Not in our library10.1046/j.1523-1755.64.s86.7.x

  56. 56.

    Esteban V. Lorenzo O. Rupérez M. Suzuki Y. Mezzano S. Blanco J. (2004 ). Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J. Am. Soc. Nephrol. 15 (6), 1514–1529.

    Not in our library10.1097/01.asn.0000130564.75008.f5

  57. 57.

    Estruch R. Ros E. Salas-Salvado J. Covas M. I. Corella D. Aros F. (2013 ). Primary prevention of cardiovascular disease with a Mediterranean diet. N. Eng. J. Med. 368 (14), 1279–1290.

    Not in our library10.1056/nejmoa1200303

  58. 58.

    Fanelli C. Arias S. C. A. Machado F. G. Okuma J. K. Malheiros D. Azevedo H. (2017 ). Innate and adaptive immunity are progressively activated in parallel with renal injury in the 5/6 renal ablation model. Sci. Rep. 7 (1), 3192.

    Not in our library10.1038/s41598-017-02915-6

  59. 59.

    Faustino V. D. Arias S. C. A. Ferreira Avila V. Foresto-Neto O. Zambom F. F. F. Machado F. G. (2018 ). Simultaneous activation of innate and adaptive immunity participates in the development of renal injury in a model of heavy proteinuria. Bioscie Rep. 38 (4), 1–18.

    Not in our library10.1042/bsr20180762

  60. 60.

    Floege J. Burns M. W. Alpers C. E. Yoshimura A. Pritzl P. Gordon K. (1992 ). Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model. Kidney Int. 41 (2), 297–309.

    Not in our library10.1038/ki.1992.42

  61. 61.

    Foresto-Neto O. Ávila V. F. Arias S. C. A. Zambom F. F. F. Rempel L. C. T. Faustino V. D. (2018 ). NLRP3 inflammasome inhibition ameliorates tubulointerstitial injury in the remnant kidney model. Lab. Invest. 98 (6), 773–782.

    Not in our library10.1038/s41374-018-0029-4

  62. 62.

    Francescato H. D. Costa R. S. Scavone C. Coimbra T. M. (2007 ). Parthenolide reduces cisplatin-induced renal damage. Toxicology 230 (1), 64–75.

    Not in our library10.1016/j.tox.2006.10.025

  63. 63.
    The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism · 2014
    No notice
  64. 64.

    Fujihara C. K. Velho M. Malheiros D. M. Zatz R. (2005 ). An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int. 67 (5), 1913–1924.

    Not in our library10.1111/j.1523-1755.2005.00290.x

  65. 65.

    Fujihara C. K. Antunes G. R. Mattar A. L. Malheiros D. M. Vieira J. M. Zatz R. (2007 b). Chronic inhibition of nuclear factor-kappaB attenuates renal injury in the 5/6 renal ablation model. Am. J. Physiol. Renal Physiol. 292 (1), F92–F99.

    Not in our library10.1152/ajprenal.00184.2006

  66. 66.

    Fujihara C. K. Malheiros D. M. Zatz R. (2007 a). Losartan–hydrochlorothiazide association promotes lasting blood pressure normalization and completely arrests long-term renal injury in the 5/6 ablation model. Am. J. Physiol. Renal Physiol. 292 (6), F1810–F1818.

    Not in our library10.1152/ajprenal.00521.2006

  67. 67.

    Gamboa J. L. Pretorius M. Todd-Tzanetos D. R. Luther J. M. Yu C. Ikizler T. A. (2012 ). Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. J. Am. Soc. Nephrol. 23 (2), 334–342.

    Not in our library10.1681/asn.2011030287

  68. 68.

    Gao B. Tu P. Bian X. Chi L. Ru H. Lu K. (2017 ). Profound perturbation induced by triclosan exposure in mouse gut microbiome: a less resilient microbial community with elevated antibiotic and metal resistomes. BMC Pharmacol. Toxicol. 18 (1), 46.

    Not in our library10.1186/s40360-017-0150-9

  69. 69.

    Ge H. Li X. Weiszmann J. Wang P. Baribault H. Chen J. L. (2008 ). Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology 149 (9), 4519–4526.

    Not in our library10.1210/en.2008-0059

  70. 70.

    Geissmann F. Jung S. Littman D. R. (2003 ). Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19 (1), 71–82.

    Not in our library10.1016/s1074-7613(03)00174-2

  71. 71.

    Gilbert R. E. Wu L. L. Kelly D. J. Cox A. Wilkinson-Berka J. L. Johnston C. I. (1999 ). Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. Am. J. Pathol. 155 (2), 429–440.

    Not in our library10.1016/s0002-9440(10)65139-5

  72. 72.

    Goicoechea M. de Vinuesa S. G. Verdalles U. Ruiz-Caro C. Ampuero J. Rincón A. (2010 ). Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin. J. Am. Soc. Nephrol. 5 (8), 1388–1393.

    Not in our library10.2215/cjn.01580210

  73. 73.

    Goicoechea M., Garcia de Vinuesa S. Verdalles U. Verde E. Macias N. Santos A. (2015 ). Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am. J. Kidney Dis. 65 (4), 543–549.

    Not in our library10.1053/j.ajkd.2014.11.016

  74. 74.

    Gonçalves A. R. Fujihara C. K. Mattar A. L. Malheiros D. M., IeL, Noronha, de Nucci G. (2004 ). Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory. Am. J. Physiol. Renal Physiol. 286 (5), F945–F954.

    Not in our library10.1152/ajprenal.00238.2003

  75. 75.

    Gräfe M. Auch-Schwelk W. Zakrzewicz A. Regitz-Zagrosek V. Bartsch P. Graf K. (1997 ). Angiotensin II–induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res. 81 (5), 804–811.

    Not in our library10.1161/01.res.81.5.804

  76. 76.

    Griffin K. A. Bidani A. K. (2006 ). Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade. Clin. J. Am. Soc. Nephrol. 1 (5), 1054–1065.

    Not in our library10.2215/cjn.02231205

  77. 77.

    Guida B. Germano R. Trio R. Russo D. Memoli B. Grumetto L. (2014 ). Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: a randomized clinical trial. Nutr. Metab. Cardiovasc. Dis. 24 (9), 1043–1049.

    Not in our library10.1016/j.numecd.2014.04.007

  78. 78.

    Halkjaer S. I. Christensen A. H. Lo B. Z. S. Browne P. D. Gunther S. Hansen L. H. (2018 ). Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut 67 (12), 2107–2115.

    Not in our library10.1136/gutjnl-2018-316434

  79. 79.

    Hara T. Kimura I. Inoue D. Ichimura A. Hirasawa A. (2013 ). Free fatty acid receptors and their role in regulation of energy metabolism. Rev. Physiol. Biochem. Pharmacol. 164, 77–116.

    Not in our library10.1007/112_2013_13

  80. 80.

    Hempel S. Newberry S. J. Maher A. R. Wang Z. Miles J. N. Shanman R. (2012 ). Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. Jama. 307 (18), 1959–1969.

    Not in our library10.1001/jama.2012.3507

  81. 81.

    Henkel T. Machleidt T. Alkalay I. Krönke M. Ben-Neriah Y. Baeuerle P. A. (1993 ). Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B. Nature 6442 (365), 182–185.

    Not in our library10.1038/365182a0

  82. 82.

    Herbert D. R. Holscher C. Mohrs M. Arendse B. Schwegmann A. Radwanska M. (2004 ). Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology. Immunity 20 (5), 623–635.

    Not in our library10.1016/s1074-7613(04)00107-4

  83. 83.

    Heymann F. Meyer-Schwesinger C. Hamilton-Williams E. E. Hammerich L. Panzer U. Kaden S. (2009 ). Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. J. Clin. Investig. 119 (5), 1286–1297.

    Not in our library10.1172/jci38399

  84. 84.

    Hida M. Aiba Y. Sawamura S. Suzuki N. Satoh T. Koga Y. (1996 ). Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron. 74 (2), 349–355.

    Not in our library10.1159/000189334

  85. 85.

    Hill C. Guarner F. Reid G. Gibson G. R. Merenstein D. J. Pot B. (2014 ). Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11 (8), 506–514.

    Not in our library10.1038/nrgastro.2014.66

  86. 86.

    Hisada Y. Sugaya T. Yamanouchi M. Uchida H. Fujimura H. Sakurai H. (1999 ). Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. J. Clin. Invest. 103 (5), 627–635.

    Not in our library10.1172/jci2454

  87. 87.

    Hoesel L. M. Neff T. A. Neff S. B. Younger J. G. Olle E. W. Gao H. (2005 ). Harmful and protective roles of neutrophils in sepsis. Shock 24 (1), 40–47.

    Not in our library10.1097/01.shk.0000170353.80318.d5

  88. 88.

    Hoste E. A. Bagshaw S. M. Bellomo R. Cely C. M. Colman R. Cruz D. N. (2015 ). Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med. 41 (8), 1411–1423.

    Not in our library10.1007/s00134-015-3934-7

  89. 89.

    Hughes-Large J. M. Pang D. K. Robson D. L. Chan P. Toma J. Borradaile N. M. (2014 ). Niacin receptor activation improves human microvascular endothelial cell angiogenic function during lipotoxicity. Atherosclerosis. 237 (2), 696–704.

    Not in our library10.1016/j.atherosclerosis.2014.10.090

  90. 90.

    Human Microbiome Project C. (2012 ). Structure, function and diversity of the healthy human microbiome. Nature 486 (7402), 207–214.

    Not in our library10.1038/nature11234

  91. 91.

    Iyer S. S. Pulskens W. P. Sadler J. J. Butter L. M. Teske G. J. Ulland T. K. (2009 ). Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc. Natl. Acad. Sci. U. S. A. 106 (48), 20388–20393.

    Not in our library10.1073/pnas.0908698106

  92. 92.

    Jang H. R. Gandolfo M. T. Ko G. J. Satpute S. Racusen L. Rabb H. (2009 ). Early exposure to germs modifies kidney damage and inflammation after experimental ischemia–reperfusion injury. Am. J. Physiol. Renal Physiol. 297 (5), F1457–F1465.

    Not in our library10.1152/ajprenal.90769.2008

  93. 93.

    Jerke U. Hernandez D. P. Beaudette P. Korkmaz B. Dittmar G. Kettritz R. (2015 ). Neutrophil serine proteases exert proteolytic activity on endothelial cells. Kidney Int. 88 (4), 764–775.

    Not in our library10.1038/ki.2015.159

  94. 94.

    Jimenez E. Fernandez L. Marin M. L. Martin R. Odriozola J. M. Nueno-Palop C. (2005 ). Isolation of commensal bacteria from umbilical cord blood of healthy neonates born by cesarean section. Curr. Microbiol. 51 (4), 270–274.

    Not in our library10.1007/s00284-005-0020-3

  95. 95.

    Jimenez E. Marin M. L. Martin R. Odriozola J. M. Olivares M. Xaus J. (2008 ). Is meconium from healthy newborns actually sterile? Res. Microbiol. 159 (3), 187–193.

    Not in our library10.1016/j.resmic.2007.12.007

  96. 96.

    Jo S. K. Sung S. A. Cho W. Y. Go K. J. Kim H. K. (2006 ). Macrophages contribute to the initiation of ischaemic acute renal failure in rats. Nephrol. Dialysis Transplant. 21 (5), 1231–1239.

    Not in our library10.1093/ndt/gfk047

  97. 97.

    Johnson R. J. Alpers C. E. Yoshimura A. Lombardi D. Pritzl P. Floege J. (1992 ). Renal injury from angiotensin II–mediated hypertension. Hypertension 19 (5), 464–474.

    Not in our library10.1161/01.hyp.19.5.464

  98. 98.
    CODEX-aligned dietary fiber definitions help to bridge the ‘fiber gap’ · 2014
    No notice
  99. 99.

    Kagami S. Border W. A. Miller D. E. Noble N. A. (1994 ). Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J. Clin. Invest. 93 (6), 2431–2437.

    Not in our library10.1172/jci117251

  100. 100.

    Kalantar-Zadeh K. Kopple J. D. Deepak S. Block D. Block G. (2002 ). Food intake characteristics of hemodialysis patients as obtained by Food Frequency Questionnaire. J. Renal Nutr. 12 (1), 17–31.

    Not in our library10.1053/jren.2002.29598

  101. 101.
    Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study · 2017
    No notice
  102. 102.

    Karasawa K. Asano K. Moriyama S. Ushiki M. Monya M. Iida M. (2015 ). Vascular-resident CD169-positive monocytes and macrophages control neutrophil accumulation in the kidney with ischemia–reperfusion injury. J. Am. Soc. Nephrol. 26 (4), 896–906.

    Not in our library10.1681/asn.2014020195

  103. 103.

    Kawakami T. Lichtnekert J. Thompson L. J. Karna P. Bouabe H. Hohl T. M. (2013 ). Resident renal mononuclear phagocytes comprise five discrete populations with distinct phenotypes and functions. J. Immunol. 191 (6), 3358–3372.

    Not in our library10.4049/jimmunol.1300342

  104. 104.

    Kayabasi H. Yilmaz Z. Sit D. Kadiroglu A. K. Yilmaz E. (2013 ). The effects of losartan on oxidative stress and inflammation in non-diabetic patients undergoing chronic hemodialysis. Eur. Rev. Med. Pharmacol. Sci. 17 (2), 235–242.

    Not in our library

  105. 105.

    Kim H. J. Lee D. W. Ravichandran K., OK, D., Akcay A. Nguyen Q. (2013 ). NLRP3 inflammasome knockout mice are protected against ischemic but not cisplatin-induced acute kidney injury. J. Pharmacol.Exp. Ther. 346 (3), 465–472.

    Not in our library10.1124/jpet.113.205732

  106. 106.

    Kim S. M. Lee S. H. Kim Y. G. Kim S. Y. Seo J. W. Choi Y. W. (2015 ). Hyperuricemia-induced NLRP3 activation of macrophages contributes to the progression of diabetic nephropathy. Am. J. Physiol. Renal Physiol. 308 (9), F993–F1003.

    Not in our library10.1152/ajprenal.00637.2014

  107. 107.

    Kimura I. Inoue D. Maeda T. Hara T. Ichimura A. Miyauchi S. (2011 ). Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein–coupled receptor 41 (GPR41). Proc. Natl. Acad. Sci. U. S. A. 108 (19), 8030–8035.

    Not in our library10.1073/pnas.1016088108

  108. 108.

    Kinsey G. R. Sharma R. Huang L. Li L. Vergis A. L. Ye H. (2009 ). Regulatory T cells suppress innate immunity in kidney ischemia–reperfusion injury. J. Am. Soc. Nephrol. 20 (8), 1744–1753.

    Not in our library10.1681/asn.2008111160

  109. 109.

    Konstantinov S. R. Smidt H. de Vos W. M. Bruijns S. C. Singh S. K. Valence F. (2008 ). S layer protein A of Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell functions. Proc. Natl. Acad. Sci. U. S. A. 105 (49), 19474–19479.

    Not in our library10.1073/pnas.0810305105

  110. 110.

    Koropatkin N. M. Cameron E. A. Martens E. C. (2012 ). How glycan metabolism shapes the human gut microbiota. Nat. Rev. Microbiol. 10 (5), 323–335.

    Not in our library10.1038/nrmicro2746

  111. 111.

    Kostylina G. Simon D. Fey M. F. Yousefi S. Simon H. U. (2008 ). Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A). Cell Death Differ. 15 (1), 134–142.

    Not in our library10.1038/sj.cdd.4402238

  112. 112.

    Kramer A. A. Postler G. Salhab K. F. Mendez C. Carey L. C. Rabb H. (1999 ). Renal ischemia/reperfusion leads to macrophage-mediated increase in pulmonary vascular permeability. Kidney Int. 55 (6), 2362–2367.

    Not in our library10.1046/j.1523-1755.1999.00460.x

  113. 113.

    Krishnamurthy V. M. Wei G. Baird B. C. Murtaugh M. Chonchol M. B. Raphael K. L. (2012 ). High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int. 81 (3), 300–306.

    Not in our library10.1038/ki.2011.355

  114. 114.
    Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials · 2016
    No notice
  115. 115.

    Kruger B. Krick S. Dhillon N. Lerner S. M. Ames S. Bromberg J. S. (2009 ). Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc. Natl. Acad. Sci. U. S. A. 106 (9), 3390–3395.

    Not in our library10.1073/pnas.0810169106

  116. 116.

    Kurts C. Panzer U. Anders H. J. Rees A. J. (2013 ). The immune system and kidney disease: basic concepts and clinical implications. Nat. Rev. Immunol. 13 (10), 738–753.

    Not in our library10.1038/nri3523

  117. 117.

    Latz E. Xiao T. S. Stutz A. (2013 ). Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13 (6), 397–411.

    Not in our library10.1038/nri3452

  118. 118.

    Le Poul E. Loison C. Struyf S. Springael J. Y. Lannoy V. Decobecq M. E. (2003 ). Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 278 (28), 25481–25489.

    Not in our library10.1074/jbc.m301403200

  119. 119.

    Lee F. T. Cao Z. Long D. M. Panagiotopoulos S. Jerums G. Cooper M. E. (2004 ). Interactions between angiotensin II and NF-kappaB–dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J. Am. Soc. Nephrol. 15 (8), 2139–2151.

    Not in our library10.1097/01.asn.0000135055.61833.a8

  120. 120.

    Lee H. Nho D. Chung H. S. Lee H. Shin M. K. Kim S. H. (2010 ). CD4+CD25+ regulatory T cells attenuate cisplatin-induced nephrotoxicity in mice. Kidney Int. 78 (11), 1100–1109.

    Not in our library10.1038/ki.2010.139

  121. 121.

    Lee S. Huen S. Nishio H. Nishio S. Lee H. K. Choi B. S. (2011 ). Distinct macrophage phenotypes contribute to kidney injury and repair. J. Am. Soc. Nephrol. 22 (2), 317–326.

    Not in our library10.1681/asn.2009060615

  122. 122.

    Lee J. W. Bae E. Kwon S. H. Yu M. Y. Cha R. H. Lee H. (2018 ). Transcriptional modulation of the T helper 17/interleukin 17 axis ameliorates renal ischemia–reperfusion injury. Nephrol. Dialysis Transplant. 34, 1481–1498.

    Not in our library10.1093/ndt/gfy370

  123. 123.

    Leemans J. C. Stokman G. Claessen N. Rouschop K. M. Teske G. J. Kirschning C. J. (2005 ). Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J. Clin. Investig. 115 (10), 2894–2903.

    Not in our library10.1172/jci22832

  124. 124.
    The role of Toll-like receptor 2 in inflammation and fibrosis during progressive renal injury. · 2009
    Not checked
  125. 125.
    The role of neutrophils in immune dysfunction during severe inflammation · 2016
    No notice
  126. 126.

    Lemley K. V. Kriz W. (1991 ). Anatomy of the renal interstitium. Kidney Int. 39 (3), 370–381.

    Not in our library10.1038/ki.1991.49

  127. 127.

    Lewis E. J. Hunsicker L. G. Bain R. P. Rohde R. D. (1993 ). The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329 (20), 1456–1462.

    Not in our library10.1056/nejm199311113292004

  128. 128.

    Lewis E. J. Hunsicker L. G. Clarke W. R. Berl T. Pohl M. A. Lewis J. B. (2001 ). Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345 (12), 851–860.

    Not in our library10.1056/nejmoa011303

  129. 129.

    Li J. Tang Y. Tang P. M. K. Lv J. Huang X. R. Carlsson-Skwirut C. (2018 ). Blocking macrophage migration inhibitory factor protects against cisplatin-induced acute kidney injury in mice. Mol Ther. 26 (10), 2523–2532.

    Not in our library10.1016/j.ymthe.2018.07.014

  130. 130.

    Liano F. Felipe C. Tenorio M. T. Rivera M. Abraira V., Saez-de-Urturi J. M. (2007 ). Long-term outcome of acute tubular necrosis: a contribution to its natural history. Kidney Int. 71 (7), 679–686.

    Not in our library10.1038/sj.ki.5002086

  131. 131.

    Lin C. S. Lee W. L. Hung Y. J. Lee D. Y. Chen K. F. Chi W. C. (2012 ). Prevalence of hyperuricemia and its association with antihypertensive treatment in hypertensive patients in Taiwan. Int. J. Cardiol. 156 (1), 41–46.

    Not in our library10.1016/j.ijcard.2010.10.033

  132. 132.

    Liu L. Kou P. Zeng Q. Pei G. Li Y. Liang H. (2012 ). CD4+ T Lymphocytes, especially TH2 cells, contribute to the progress of renal fibrosis. Am. J. Nephrol. 36 (4), 386–396.

    Not in our library10.1159/000343283

  133. 133.

    Liu J. Krautzberger A. M. Sui S. H. Hofmann O. M. Chen Y. Baetscher M. (2014 ). Cell-specific translational profiling in acute kidney injury. J. Clin. Investig. 124 (3), 1242–1254.

    Not in our library10.1172/jci72126

  134. 134.

    Liu P. Chen Y. Wang B. Zhang F. Wang D. Wang Y. (2015 ). Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. Clin Endocrinol (Oxf). 83 (4), 475–482.

    Not in our library10.1111/cen.12673

  135. 135.
    The healthy human microbiome · 2016
    No notice
  136. 136.

    López-Franco O. Hernández-Vargas P. Ortiz-Muñoz G. Sanjuán G. Suzuki Y. Ortega L. (2006 ). Parthenolide modulates the NF-kappaB–mediated inflammatory responses in experimental atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26 (8), 1864–1870.

    Not in our library10.1161/01.atv.0000229659.94020.53

  137. 137.

    Lu L. H. Oh D. J. Dursun B. He Z. Hoke T. S. Faubel S. (2008 ). Increased macrophage infiltration and fractalkine expression in cisplatin-induced acute renal failure in mice. J. Pharmacol.Exp. Ther. 324 (1), 111–117.

    Not in our library10.1124/jpet.107.130161

  138. 138.

    Machado F. G. Poppi E. P. Fanelli C. Malheiros D. M. Zatz R. Fujihara C. K. (2008 ). AT1 blockade during lactation as a model of chronic nephropathy: mechanisms of renal injury. Am. J. Physiol. Renal Physiol. 294 (6), F1345–F1353.

    Not in our library10.1152/ajprenal.00020.2008

  139. 139.

    MacIver N. J. Michalek R. D. Rathmell J. C. (2013 ). Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 31, 259–283.

    Not in our library10.1146/annurev-immunol-032712-095956

  140. 140.

    Makkawi S. Camara-Lemarroy C. Metz L. (2018 ). Fecal microbiota transplantation associated with 10 years of stability in a patient with SPMS. Neurol. Neuroimmunol. Neuroinflammation 5 (4), e459.

    Not in our library10.1212/nxi.0000000000000459

  141. 141.

    Maravitsa P. Adamopoulou M. Pistiki A. Netea M. G. Louis K. Giamarellos-Bourboulis E. J. (2016 ). Systemic over-release of interleukin-17 in acute kidney injury after septic shock: clinical and experimental evidence. Immunol. Lett. 178, 68–76.

    Not in our library10.1016/j.imlet.2016.08.002

  142. 142.

    Marques V. P. Goncalves G. M. Feitoza C. Q. Cenedeze M. A. Fernandes Bertocchi A. P. Damiao M. J. (2006 ). Influence of TH1/TH2 switched immune response on renal ischemia–reperfusion injury. Nephron Exp. Nephrol. 104 (1), e48–e56.

    Not in our library10.1159/000093676

  143. 143.

    Martin V. Maldonado-Barragan A. Moles L. Rodriguez-Banos M. Campo R. D. Fernandez L. (2012 ). Sharing of bacterial strains between breast milk and infant feces. J. Hum. Lactation 28 (1), 36–44.

    Not in our library10.1177/0890334411424729

  144. 144.

    Martina M. N. Noel S. Saxena A. Bandapalle S. Majithia R. Jie C. (2016 ). Double-negative alphabeta T cells are early responders to aki and are found in human kidney. J. Am. Soc. Nephrol. 27 (4), 1113–1123.

    Not in our library10.1681/asn.2014121214

  145. 145.
    Resistant Starches Types 2 and 4 Have Differential Effects on the Composition of the Fecal Microbiota in Human Subjects · 2010
    No notice
  146. 146.

    McIntyre C. W. Harrison L. E. Eldehni M. T. Jefferies H. J. Szeto C. C. John S. G. (2011 ). Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J. Am. Soc. Nephrol. 6 (1), 133–141.

    Not in our library10.2215/cjn.04610510

  147. 147.

    Meijers B. K. Claes K. Bammens B. de Loor H. Viaene L. Verbeke K. (2010 a). p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J. Am. Soc. Nephrol. 5 (7), 1182–1189.

    Not in our library10.2215/cjn.07971109

  148. 148.

    Meijers B. K. De Preter V. Verbeke K. Vanrenterghem Y. Evenepoel P. (2010 b). p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol. Dialysis Transplant. 25 (1), 219–224.

    Not in our library10.1093/ndt/gfp414

  149. 149.

    Merino A. Alvarez-Lara M. A. Ramirez R. Carracedo J. Martin-Malo A. Aljama P. (2012 ). Losartan prevents the development of the pro-inflammatory monocytes CD14+CD16+ in haemodialysis patients. Nephrol. Dial. Transplant. 27 (7), 2907–2912.

    Not in our library10.1093/ndt/gfr767

  150. 150.

    Monteiro R. M. Camara N. O. Rodrigues M. M. Tzelepis F. Damiao M. J. Cenedeze M. A. (2009 ). A role for regulatory T cells in renal acute kidney injury. Transpl. Immunol. 21 (1), 50–55.

    Not in our library10.1016/j.trim.2009.02.003

  151. 151.

    Motojima M. Hosokawa A. Yamato H. Muraki T. Yoshioka T. (2003 ). Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int. 63 (5), 1671–1680.

    Not in our library10.1046/j.1523-1755.2003.00906.x

  152. 152.

    Mulay S. R. Anders H. J. (2017 ). Crystal nephropathies: mechanisms of crystal-induced kidney injury. Nat. Rev. Nephrol. 13 (4), 226–240.

    Not in our library10.1038/nrneph.2017.10

  153. 153.

    Nakabayashi I. Nakamura M. Kawakami K. Ohta T. Kato I. Uchida K. (2011 ). Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: a preliminary study. Nephrol. Dialysis Transplant. 26 (3), 1094–1098.

    Not in our library10.1093/ndt/gfq624

  154. 154.

    Nataraj C. Oliverio M. I. Mannon R. B. Mannon P. J. Audoly L. P. Amuchastegui C. S. (1999 ). Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J. Clin. Invest. 104 (12), 1693–1701.

    Not in our library10.1172/jci7451

  155. 155.

    Nelson P. J. Rees A. J. Griffin M. D. Hughes J. Kurts C. Duffield J. (2012 ). The renal mononuclear phagocytic system. J. Am. Soc. Nephrol. 23 (2), 194–203.

    Not in our library10.1681/asn.2011070680

  156. 156.

    Nicholson J. K. Holmes E. Kinross J. Burcelin R. Gibson G. Jia W. (2012 ). Host-gut microbiota metabolic interactions. Science 336 (6086), 1262–1267.

    Not in our library10.1126/science.1223813

  157. 157.

    Nogueira E. Salomao R. Brunialti M. K. Ozaki K. S. Marques G. D. Cenedeze M. A. (2010 ). Expression of TLR-4 and -2 in peripheral mononuclear cells in renal transplant patients with TLR-4 gene polymorphism. Int. Immunopharmacol. 10 (12), 1481–1485.

    Not in our library10.1016/j.intimp.2010.09.005

  158. 158.

    Ogryzlo M. A. Urowitz M. B. Weber H. M. Houpt J. B. (1966 ). The treatment of gout and disorders of uric acid metabolism with allopurinol. Can Med Assoc J. 95 (22), 1120–1127.

    Not in our library

  159. 159.

    Okabe C. Borges R. L. de Almeida D. C. Fanelli C. Barlette G. P. Machado F. G. (2013 ). NF-kappaB activation mediates crystal translocation and interstitial inflammation in adenine overload nephropathy. Am. J. Physiol. Renal Physiol. 305 (2), F155–F163.

    Not in our library10.1152/ajprenal.00491.2012

  160. 160.

    Okabe C. Borges R. L. de Almeida D. C. Fanelli C. Barlette G. P. Machado F. G. (2013 ). NF-κB activation mediates crystal translocation and interstitial inflammation in adenine overload nephropathy. Am. J. Physiol. Renal Physiol. 305 (2), F155–F163.

    Not in our library10.1152/ajprenal.00491.2012

  161. 161.

    Ordaz-Medina S. M. González-Plascencia J., Martín del Campo F. Rojas-Campos E. Montañez-Fernández J. L. Espinoza-Gómez F. (2010 ). Is systemic inflammation of hemodialysis patients improved with the use of enalapril? Results of a randomized, double-blinded, placebo-controlled clinical trial. ASAIO J. 2010 56 (1), 37–41.

    Not in our library10.1097/mat.0b013e3181c1d830

  162. 162.

    Parikh C. R. Jani A. Mishra J. Ma Q. Kelly C. Barasch J. (2006 ). Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am. J. Transplant. 6 (7), 1639–1645.

    Not in our library10.1111/j.1600-6143.2006.01352.x

  163. 163.

    Parish I. A. Kaech S. M. (2009 ). Diversity in CD8(+) T cell differentiation. Curr. Opin. Immunol. 21 (3), 291–297.

    Not in our library10.1016/j.coi.2009.05.008

  164. 164.

    Patel R. M. Denning P. W. (2013 ). Therapeutic use of prebiotics, probiotics, and postbiotics to prevent necrotizing enterocolitis: what is the current evidence? Clin. Perinatol. 40 (1), 11–25.

    Not in our library10.1016/j.clp.2012.12.002

  165. 165.

    Pavan M. (2016 ). Influence of prebiotic and probiotic supplementation on the progression of chronic kidney disease. Minerva Urol Nefrol = Ital. J. Urol. Nephrol. 68 (2), 222–226.

    Not in our library

  166. 166.

    Perez-Cobas A. E. Gosalbes M. J. Friedrichs A. Knecht H. Artacho A. Eismann K. (2013 ). Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut 62 (11), 1591–1601.

    Not in our library10.1136/gutjnl-2012-303184

  167. 167.

    Peters C. D. Kjaergaard K. D. Nielsen C. H. Christensen K. L. Bibby B. M. Jensen J. D. (2017 ). Long-term effects of angiotensin II blockade with irbesartan on inflammatory markers in hemodialysis patients: a randomized double blind placebo controlled trial (SAFIR study). Hemodial. Int. 21 (1), 47–62.

    Not in our library10.1111/hdi.12436

  168. 168.

    Pinero-Lambea C. Ruano-Gallego D. Fernandez L. A. (2015 ). Engineered bacteria as therapeutic agents. Curr. Opin. Biotechnol. 35, 94–102.

    Not in our library10.1016/j.copbio.2015.05.004

  169. 169.

    Poesen R. Windey K. Neven E. Kuypers D. De Preter V. Augustijns P. (2016 ). The influence of CKD on colonic microbial metabolism. J. Am. Soc. Nephrol. 27 (5), 1389–1399.

    Not in our library10.1681/asn.2015030279

  170. 170.

    Prakash S. Chang T. M. (1996 ). Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nat. Med. 2 (8), 883–887.

    Not in our library10.1038/nm0896-883

  171. 171.

    Pulskens W. P. Rampanelli E. Teske G. J. Butter L. M. Claessen N. Luirink I. K. (2010 ). TLR4 promotes fibrosis but attenuates tubular damage in progressive renal injury. J. Am. Soc. Nephrol. 21 (8), 1299–1308.

    Not in our library10.1681/asn.2009070722

  172. 172.

    Pulskens W. P. Butter L. M. Teske G. J. Claessen N. Dessing M. C. Flavell R. A. (2014 ). Nlrp3 prevents early renal interstitial edema and vascular permeability in unilateral ureteral obstruction. PloS one 9 (1), e85775.

    Not in our library10.1371/journal.pone.0085775

  173. 173.

    Rabb H. Daniels F. O’Donnell M. Haq M. Saba S. R. Keane W. (2000 ). Pathophysiological role of T lymphocytes in renal ischemia–reperfusion injury in mice. Am. J. Physiol. Renal Physiol. 279 (3), F525–F531.

    Not in our library10.1152/ajprenal.2000.279.3.f525

  174. 174.

    Ranganathan N. Patel B. Ranganathan P. Marczely J. Dheer R. Chordia T. (2005 ). Probiotic amelioration of azotemia in 5/6th nephrectomized Sprague-Dawley rats. Sci. World J. 5, 652–660.

    Not in our library10.1100/tsw.2005.86

  175. 175.

    Ranganathan N. Patel B. G. Ranganathan P. Marczely J. Dheer R. Pechenyak B. (2006 ). In vitro and in vivo assessment of intraintestinal bacteriotherapy in chronic kidney disease. ASAIO J. 52 (1), 70–79.

    Not in our library10.1097/01.mat.0000191345.45735.00

  176. 176.

    Ranganathan N. Ranganathan P. Friedman E. A. Joseph A. Delano B. Goldfarb D. S. (2010 ). Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv. Ther. 27 (9), 634–647.

    Not in our library10.1007/s12325-010-0059-9

  177. 177.

    Raup-Konsavage W. M. Wang Y. Wang W. W. Feliers D. Ruan H. Reeves W. B. (2018 ). Neutrophil peptidyl arginine deiminase-4 has a pivotal role in ischemia/reperfusion-induced acute kidney injury. Kidney Int. 93 (2), 365–374.

    Not in our library10.1016/j.kint.2017.08.014

  178. 178.

    Rice J. L. Romero K. M. Galvez Davila R. M. Meza C. T. Bilderback A. Williams D. L. (2015 ). Association between adherence to the mediterranean diet and asthma in Peruvian children. Lung 193 (6), 893–899.

    Not in our library10.1007/s00408-015-9792-9

  179. 179.

    Richter C. K. Skulas-Ray A. C. Champagne C. M. Kris-Etherton P. M. (2015 ). Plant protein and animal proteins: do they differentially affect cardiovascular disease risk? Adv. Nutr. 6 (6), 712–728.

    Not in our library10.3945/an.115.009654

  180. 180.

    Rook G. A. (2013 ). Regulation of the immune system by biodiversity from the natural environment: an ecosystem service essential to health. Proc. Natl. Acad. Sci. U. S. A. 110 (46), 18360–18367.

    Not in our library10.1073/pnas.1313731110

  181. 181.

    Rooks M. G. Garrett W. S. (2016 ). Gut microbiota, metabolites and host immunity. Nat. Rev. Immunol. 16 (6), 341–352.

    Not in our library10.1038/nri.2016.42

  182. 182.

    Rosin D. L. Okusa M. D. (2011 ). Dangers within: DAMP responses to damage and cell death in kidney disease. J. Am. Soc. Nephrol. 22 (3), 416–425.

    Not in our library10.1681/asn.2010040430

  183. 183.

    Rossi M. Johnson D. W. Morrison M. Pascoe E. M. Coombes J. S. Forbes J. M. (2016 ). Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY): a randomized trial. Clin. J. Am. Soc. Nephrol. 11 (2), 223–231.

    Not in our library10.2215/cjn.05240515

  184. 184.

    Rostron A. J. Cork D. M. Avlonitis V. S. Fisher A. J. Dark J. H. Kirby J. A. (2010 ). Contribution of Toll-like receptor activation to lung damage after donor brain death. Transplantation 90 (7), 732–739.

    Not in our library10.1097/tp.0b013e3181eefe02

  185. 185.
    Gut microbiota functions: metabolism of nutrients and other food components · 2017
    No notice
  186. 186.

    Ruiz-Ortega M. Bustos C. Hernández-Presa M. A. Lorenzo O. Plaza J. J. Egido J. (1998 ). Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J. Immunol. 161 (1), 430–439.

    Not in our library

  187. 187.

    Ruiz-Ortega M. Rupérez M. Esteban V. Rodríguez-Vita J. Sánchez-López E. Carvajal G. (2006 ). Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol. Dial. Transplant. 21 (1), 16–20.

    Not in our library10.1093/ndt/gfi265

  188. 188.

    Russell W. R. Gratz S. W. Duncan S. H. Holtrop G. Ince J. Scobbie L. (2011 ). High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health. Am. J. Clin. Nutr. 93 (5), 1062–1072.

    Not in our library10.3945/ajcn.110.002188

  189. 189.
    A longitudinal analysis of diet quality scores and the risk of incident depression in the SUN Project · 2015
    No notice
  190. 190.

    Sanders S. A. Eisenthal R. Harrison R. (1997 ). NADH oxidase activity of human xanthine oxidoreductase—generation of superoxide anion. Eur. J. Biochem. 245 (3), 541–548.

    Not in our library10.1111/j.1432-1033.1997.00541.x

  191. 191.

    Sanz A. B. Sanchez-Niño M. D. Ramos A. M. Moreno J. A. Santamaria B. Ruiz-Ortega M. (2010 ). NF-kappaB in renal inflammation. J. Am. Soc. Nephrol. 21 (8), 1254–1262.

    Not in our library10.1681/asn.2010020218

  192. 192.

    Saran R. Robinson B. Abbott K. C. Agodoa L. Y. Albertus P. Ayanian J. (2017 ). US Renal Data System 2016 annual data report: epidemiology of kidney disease in the United States. Am. J. Kidney Dis. 69 ( Suppl 1), A7–A8.

    Not in our library10.1053/j.ajkd.2016.12.004

  193. 193.

    Saran R. Robinson B. Abbott K. C. Agodoa L. Y. C. Bhave N. Bragg-Gresham J. (2018 ). US Renal Data System 2017 annual data report: epidemiology of kidney disease in the United States. Am. J. Kidney Dis. 71 (3S1), A7.

    Not in our library10.1053/j.ajkd.2018.01.002

  194. 194.

    Schreck R. Meier B. Männel D. N. Dröge W. Baeuerle P. A. (1992 ). Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J. Exp. Med. 175 (5), 1181–1194.

    Not in our library10.1084/jem.175.5.1181

  195. 195.

    Shan Y. Zhang Q. Liu Z. Hu X. Liu D. (2010 ). Prevalence and risk factors associated with chronic kidney disease in adults over 40 years: a population study from Central China. Nephrology (Carlton). 15 (3), 354–361.

    Not in our library10.1111/j.1440-1797.2009.01249.x

  196. 196.

    Shenderov B. A. (2013 ). Metabiotics: novel idea or natural development of probiotic conception. Microbial Ecol. Health Dis. 24, 1–8.

    Not in our library10.3402/mehd.v24i0.20399

  197. 197.

    Shigeoka A. A. Holscher T. D. King A. J. Hall F. W. Kiosses W. B. Tobias P. S. (2007 ). TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways. J. Immunol. 178 (10), 6252–6258.

    Not in our library10.4049/jimmunol.178.10.6252

  198. 198.

    Shigeoka A. A. Kambo A. Mathison J. C. King A. J. Hall W. F. da Silva Correia J. (2010 a). Nod1 and nod2 are expressed in human and murine renal tubular epithelial cells and participate in renal ischemia reperfusion injury. J. Immunol. 184 (5), 2297–2304.

    Not in our library10.4049/jimmunol.0903065

  199. 199.

    Shigeoka A. A. Mueller J. L. Kambo A. Mathison J. C. King A. J. Hall W. F. (2010 b). An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia–reperfusion injury. J. Immunol. 185 (10), 6277–6285.

    Not in our library10.4049/jimmunol.1002330

  200. 200.

    Shimada K. Yazaki Y. (1978 ). Binding sites for angiotensin II in human mononuclear leucocytes. J. Biochem. 84 (4), 1013–1015.

    Not in our library10.1093/oxfordjournals.jbchem.a132183

  201. 201.

    Silk D. B. Davis A. Vulevic J. Tzortzis G. Gibson G. R. (2009 ). Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Alimentary Pharmacol. Ther. 29 (5), 508–518.

    Not in our library10.1111/j.1365-2036.2008.03911.x

  202. 202.

    Simenhoff M. L. Dunn S. R. Zollner G. P. Fitzpatrick M. E. Emery S. M. Sandine W. E. (1996 ). Biomodulation of the toxic and nutritional effects of small bowel bacterial overgrowth in end-stage kidney disease using freeze-dried Lactobacillus acidophilus. Mineral Electrolyte Metab. 22 (1-3), 92–96.

    Not in our library

  203. 203.

    Singbartl K. Formeck C. L. Kellum J. A. (2019 ). Kidney–immune system crosstalk in AKI. Semin Nephrol. 39 (1), 96–106.

    Not in our library10.1016/j.semnephrol.2018.10.007

  204. 204.

    Singh R. van Nood E. Nieuwdorp M. van Dam B. Berge I. J. Geerlings S. E. (2014 ). Donor feces infusion for eradication of extended spectrum beta-lactamase producing Escherichia coli in a patient with end stage renal disease. Clin. Microbiol. Infect. 20 (11), O977–O978.

    Not in our library10.1111/1469-0691.12683

  205. 205.

    Sirich T. L. Plummer N. S. Gardner C. D. Hostetter T. H. Meyer T. W. (2014 ). Effect of increasing dietary fiber on plasma levels of colon-derived solutes in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 9 (9), 1603–1610.

    Not in our library10.2215/cjn.00490114

  206. 206.

    Siu Y. P. Leung K. T. Tong M. K. Kwan T. H. (2006 ). Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am. J. Kidney Dis. 47 (1), 51–59.

    Not in our library10.1053/j.ajkd.2005.10.006

  207. 207.

    Smith P. M. Howitt M. R. Panikov N. Michaud M. Gallini C. A. Bohlooly Y. M. (2013 ). The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341 (6145), 569–573.

    Not in our library10.1126/science.1241165

  208. 208.

    Snelgrove S. L. Lo C. Hall P. Lo C. Y. Alikhan M. A. Coates P. T. (2017 ). Activated renal dendritic cells cross present intrarenal antigens after ischemia–reperfusion injury. Transplantation 101 (5), 1013–1024.

    Not in our library10.1097/tp.0000000000001427

  209. 209.

    So A. Thorens B. (2010 ). Uric acid transport and disease. J. Clin. Invest. 120 (6), 1791–1799.

    Not in our library10.1172/jci42344

  210. 210.

    Sola R. Godas G. Ribalta J. Vallve J. C. Girona J. Anguera A. (2007 ). Effects of soluble fiber (Plantago ovata husk) on plasma lipids, lipoproteins, and apolipoproteins in men with ischemic heart disease. Am. J. Clin. Nutr. 85 (4), 1157–1163.

    Not in our library10.1093/ajcn/85.4.1157

  211. 211.

    Soty M. Penhoat A. Amigo-Correig M. Vinera J. Sardella A. Vullin-Bouilloux F. (2015 ). A gut–brain neural circuit controlled by intestinal gluconeogenesis is crucial in metabolic health. Mol Med. 4 (2), 106–117.

    Not in our library10.1016/j.molmet.2014.12.009

  212. 212.

    Stamatiades E. G. Tremblay M. E. Bohm M. Crozet L. Bisht K. Kao D. (2016 ). Immune monitoring of trans-endothelial transport by kidney-resident macrophages. Cell. 166 (4), 991–1003.

    Not in our library10.1016/j.cell.2016.06.058

  213. 213.

    Stenvinkel P. Andersson P. Wang T. Lindholm B. Bergström J. Palmblad J. (1999 ). Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure? J. Intern. Med. 246 (5), 503–507.

    Not in our library10.1046/j.1365-2796.1999.00560.x

  214. 214.

    Stubbs J. R. House J. A. Ocque A. J. Zhang S. Johnson C. Kimber C. (2016 ). Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J. Am. Soc. Nephrol. 27 (1), 305–313.

    Not in our library10.1681/asn.2014111063

  215. 215.

    Surawicz C. M. Brandt L. J. Binion D. G. Ananthakrishnan A. N. Curry S. R. Gilligan P. H. (2013 ). Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 108 (4), 478–98; quiz 99.

    Not in our library10.1038/ajg.2013.4

  216. 216.

    Tadagavadi R. K. Reeves W. B. (2010 ). Renal dendritic cells ameliorate nephrotoxic acute kidney injury. J. Am. Soc. Nephrol. 21 (1), 53–63.

    Not in our library10.1681/asn.2009040407

  217. 217.

    Takayama F. Taki K. Niwa T. (2003 ). Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am. J. Kidney Dis. 41 ( Suppl 1), S142–S145.

    Not in our library10.1053/ajkd.2003.50104

  218. 218.

    Taki K. Takayama F. Niwa T. (2005 ). Beneficial effects of bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. J. Renal Nutr. 15 (1), 77–80.

    Not in our library10.1053/j.jrn.2004.09.028

  219. 219.

    Takiishi T. Korf H. Van Belle T. L. Robert S. Grieco F. A. Caluwaerts S. (2012 ). Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J. Clin. Investig. 122 (5), 1717–1725.

    Not in our library10.1172/jci60530

  220. 220.

    Tang W. H. Wang Z. Kennedy D. J. Wu Y. Buffa J. A. Agatisa-Boyle B. (2015 ). Gut microbiota–dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 116 (3), 448–455.

    Not in our library10.1161/circresaha.116.305360

  221. 221.

    Teles F. Machado F. G. Ventura B. H. Malheiros D. M. Fujihara C. K. Silva L. F. (2009 ). Regression of glomerular injury by losartan in experimental diabetic nephropathy. Kidney Int. 75 (1), 72–79.

    Not in our library10.1038/ki.2008.528

  222. 222.

    Thorburn A. N. McKenzie C. I. Shen S. Stanley D. Macia L. Mason L. J. (2015 ). Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites. Nat. Commun. 6 236, 7320.

    Not in our library10.1038/ncomms8320

  223. 223.

    Thornton M. A. Winn R. Alpers C. E. Zager R. A. (1989 ). An evaluation of the neutrophil as a mediator of in vivo renal ischemic–reperfusion injury. Am. J. Pathol. 135 (3), 509–515.

    Not in our library

  224. 224.

    Tittel A. P. Heuser C. Ohliger C. Knolle P. A. Engel D. R. Kurts C. (2011 ). Kidney dendritic cells induce innate immunity against bacterial pyelonephritis. J. Am. Soc. Nephrol. 22 (8), 1435–1441.

    Not in our library10.1681/asn.2010101072

  225. 225.

    Trentin-Sonoda M. da Silva R. C. Kmit F. V. Abrahao M. V. Monnerat Cahli G. Brasil G. V. (2015 ). Knockout of Toll-like receptors 2 and 4 prevents renal ischemia–reperfusion–induced cardiac hypertrophy in mice. PloS one 10 (10), e0139350.

    Not in our library10.1371/journal.pone.0139350

  226. 226.

    Usami M. Kishimoto K. Ohata A. Miyoshi M. Aoyama M. Fueda Y. (2008 ). Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells. Nutr. Res. 28 (5), 321–328.

    Not in our library10.1016/j.nutres.2008.02.012

  227. 227.

    Valette X. Savary B. Nowoczyn M. Daubin C. Pottier V. Terzi N. (2013 ). Accuracy of plasma neutrophil gelatinase-associated lipocalin in the early diagnosis of contrast-induced acute kidney injury in critical illness. Intensive Care Med. 39 (5), 857–865.

    Not in our library10.1007/s00134-013-2826-y

  228. 228.

    Vandenbroucke K. de Haard H. Beirnaert E. Dreier T. Lauwereys M. Huyck L. (2010 ). Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol. 3 (1), 49–56.

    Not in our library10.1038/mi.2009.116

  229. 229.

    Vandeputte D. Falony G. Vieira-Silva S. Wang J. Sailer M. Theis S. (2017 ). Prebiotic inulin-type fructans induce specific changes in the human gut microbiota. Gut 66 (11), 1968–1974.

    Not in our library10.1136/gutjnl-2016-313271

  230. 230.

    Vaziri N. D. Wong J. Pahl M. Piceno Y. M. Yuan J. DeSantis T. Z. (2013 ). Chronic kidney disease alters intestinal microbial flora. Kidney Int. 83 (2), 308–315.

    Not in our library10.1038/ki.2012.345

  231. 231.

    Vaziri N. D. Yuan J. Nazertehrani S. Ni Z. Liu S. (2013 ). Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am. J. Nephrol. 38 (2), 99–103.

    Not in our library10.1159/000353764

  232. 232.
    High Amylose Resistant Starch Diet Ameliorates Oxidative Stress, Inflammation, and Progression of Chronic Kidney Disease · 2014
    No notice
  233. 233.

    Venkatachalam M. A. Griffin K. A. Lan R. Geng H. Saikumar P. Bidani A. K. (2010 ). Acute kidney injury: a springboard for progression in chronic kidney disease. Am. J. Physiol. Renal Physiol. 298 (5), F1078–F1094.

    Not in our library10.1152/ajprenal.00017.2010

  234. 234.

    Verzola D. Cappuccino L. D’Amato E. Villaggio B. Gianiorio F. Mij M. (2014 ). Enhanced glomerular Toll-like receptor 4 expression and signaling in patients with type 2 diabetic nephropathy and microalbuminuria. Kidney Int. 86 (6), 1229–1243.

    Not in our library10.1038/ki.2014.116

  235. 235.

    Vinolo M. A. Rodrigues H. G. Hatanaka E. Sato F. T. Sampaio S. C. Curi R. (2011 ). Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J. Nutr. Biochem. 22 (9), 849–855.

    Not in our library10.1016/j.jnutbio.2010.07.009

  236. 236.

    Vrieze A. Van Nood E. Holleman F. Salojarvi J. Kootte R. S. Bartelsman J. F. (2012 ). Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143 (4), 913–6 e7.

    Not in our library10.1053/j.gastro.2012.06.031

  237. 237.

    Wanders D. Graff E. C. Judd R. L. (2012 ). Effects of high fat diet on GPR109A and GPR81 gene expression. Biochemi. Biophysi. Res. Commun. 425 (2), 278–283.

    Not in our library10.1016/j.bbrc.2012.07.082

  238. 238.

    Wang Y. H. Zhang Y. G. (2017 ). Kidney and innate immunity. Immunol. Lett. 183, 73–78.

    Not in our library10.1016/j.imlet.2017.01.011

  239. 239.

    Wang H. B. Wang P. Y. Wang X. Wan Y. L. Liu Y. C. (2012 ). Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein claudin-1 transcription. Digest. Dis. Scie. 57 (12), 3126–3135.

    Not in our library10.1007/s10620-012-2259-4

  240. 240.

    Wang I. K. Lai H. C. Yu C. J. Liang C. C. Chang C. T. Kuo H. L. (2012 ). Real-time PCR analysis of the intestinal microbiotas in peritoneal dialysis patients. Appl. Environ. Microbiol. 78 (4), 1107–1112.

    Not in our library10.1128/aem.05605-11

  241. 241.
    Molecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance · 2014
    No notice
  242. 242.

    Wang R. Chen T. Wang C. Zhang Z. Wang X. M. Li Q. (2018 ). Flt3 inhibition alleviates chronic kidney disease by suppressing CD103+ dendritic cell–mediated T cell activation. Nephrol. Dialysis Transplant.

    Not in our library10.1093/ndt/gfy385

  243. 243.

    Watanabe H. Miyamoto Y. Honda D. Tanaka H. Wu Q. Endo M. (2013 ). p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. Kidney Int. 83 (4), 582–592.

    Not in our library10.1038/ki.2012.448

  244. 244.

    Watson C. (1899 ). Uric acid and gout: some points in the physiology of uric acid. Br Med J. 1 (1987), 205–207.

    Not in our library10.1136/bmj.1.1987.205

  245. 245.

    Wen H. Miao E. A. Ting J. P. (2013 ). Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity 39 (3), 432–441.

    Not in our library10.1016/j.immuni.2013.08.037

  246. 246.

    Wikoff W. R. Anfora A. T. Liu J. Schultz P. G. Lesley S. A. Peters E. C. (2009 ). Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. U. S. A. 106 (10), 3698–3703.

    Not in our library10.1073/pnas.0812874106

  247. 247.

    Wong J. Piceno Y. M. DeSantis T. Z. Pahl M. Andersen G. L. Vaziri N. D. (2014 ). Expansion of urease- and uricase-containing, indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD. Am. J. Nephrol. 39 (3), 230–237.

    Not in our library10.1159/000360010

  248. 248.

    Wu H. Chen G. Wyburn K. R. Yin J. Bertolino P. Eris J. M. (2007 ). TLR4 activation mediates kidney ischemia/reperfusion injury. J. Clin. Investig. 117 (10), 2847–2859.

    Not in our library10.1172/jci31008

  249. 249.

    Wu H. Ma J. Wang P. Corpuz T. M. Panchapakesan U. Wyburn K. R. (2010 ). HMGB1 contributes to kidney ischemia reperfusion injury. J. Am. Soc. Nephrol. 21 (11), 1878–1890.

    Not in our library10.1681/asn.2009101048

  250. 250.

    Wynn T. A. Barron L. (2010 ). Macrophages: master regulators of inflammation and fibrosis. Semi. Liver Dis. 30 (3), 245–257.

    Not in our library10.1055/s-0030-1255354

  251. 251.

    Xiao J. Zhang X. L. Fu C. Han R. Chen W. Lu Y. (2015 ). Soluble uric acid increases NALP3 inflammasome and interleukin-1β expression in human primary renal proximal tubule epithelial cells through the Toll-like receptor 4–mediated pathway. Int. J. Mol. Med. 35 (5), 1347–1354.

    Not in our library10.3892/ijmm.2015.2148

  252. 252.

    Yatsunenko T. Rey F. E. Manary M. J. Trehan I. Dominguez-Bello M. G. Contreras M. (2012 ). Human gut microbiome viewed across age and geography. Nature 486 (7402), 222–227.

    Not in our library10.1038/nature11053

  253. 253.

    Yoshifuji A. Wakino S. Irie J. Tajima T. Hasegawa K. Kanda T. (2016 ). Gut Lactobacillus protects against the progression of renal damage by modulating the gut environment in rats. Nephrol. Dialysis Transplant. 31 (3), 401–412.

    Not in our library10.1093/ndt/gfv353

  254. 254.

    Zhang B. Ramesh G. Uematsu S. Akira S. Reeves W. B. (2008 ). TLR4 signaling mediates inflammation and tissue injury in nephrotoxicity. J. Am. Soc. Nephrol. 19 (5), 923–932.

    Not in our library10.1681/asn.2007090982

  255. 255.

    Zhang F. Luo W. Shi Y. Fan Z. Ji G. (2012 ). Should we standardize the 1,700-year-old fecal microbiota transplantation? Am. J. Gastroenterol. 107 (11), 1755.

    Not in our library10.1038/ajg.2012.251

  256. 256.

    Zhao L. Zhang F. Ding X. Wu G. Lam Y. Y. Wang X. (2018 ). Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science 359 (6380), 1151–1156.

    Not in our library10.1126/science.aao5774

  257. 257.

    Zhu J. Yamane H. Paul W. E. (2010 ). Differentiation of effector CD4 T cell populations (*). Annu. Rev. Immunol. 28, 445–489.

    Not in our library10.1146/annurev-immunol-030409-101212

  258. 258.

    Zoccali C. Vanholder R. Massy Z. A. Ortiz A. Sarafidis P. Dekker F. W. (2017 ). The systemic nature of CKD. Nat. Rev. Nephrol. 13 (6), 344–358.

    Not in our library10.1038/nrneph.2017.52

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.